Methods of treating fibrosis and arrhythmia with neuregulin-1 fusion proteins
By developing recombinant proteins containing rhNRG-1 active domain and HER3-specific antagonist antibodies, the problems of recombinant human neuromodulin-1 in cardiovascular indications were solved, and the problems of carcinogenicity, gastrointestinal toxicity and short half-life were achieved. Carcinogenic risk, increased tolerance and simplified administration effects.
Patent Information
- Application Number
- CN202380027404.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-01
- Filing Date
- 2023-03-14
- Publication Date
- 2024-11-08
AI Technical Summary
The application of existing recombinant human neuromodulatory protein-1 (rhNRG-1) in cardiovascular indications is subject to three major limitations: it may promote cancer development, lead to gastrointestinal toxicity, and has a short half-life, requiring frequent administration.
A recombinant protein containing a fusion of the rhNRG-1 active domain with a HER3-specific antagonist antibody was developed to reduce the risk of oncogenicity and gastrointestinal toxicity by blocking HER3 signaling, and to prolong the half-life through the molecular design of the antibody.
Effectively reduces the risk of carcinogenicity of recombinant fusion proteins in the treatment of cardiac fibrosis and atrial tremor, improves gastrointestinal tolerance, and simplifies dosing regimens by prolonging half-life.
Smart Images

Figure CN118922437A_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and the benefits of U.S. Provisional Application No. 63 / 319,886, filed on March 15, 2022, and U.S. Provisional Application No. 63 / 385,705, filed on December 1, 2022, the contents of each of which are incorporated herein by reference in their entirety. Sequence Listing Incorporated by Reference
[0002] This application contains a sequence listing, which has been submitted in XML format by EFS-Web and is hereby incorporated by reference in its entirety. This XML copy was created on March 12, 2023, named SBTI-003-001WO_SeqList_ST26.xml, and is 24,646 bytes in size. Background Art
[0003] Neuregulin (NRG; heregulin, HRG), also known as glial growth factor (GGF) and new differentiation factor (NDF), is a class of glycoproteins with a molecular weight of 44KD. The NRG protein family has four members: NRG-1, NRG-2, NRG-3 and NRG-4. NRG (including NRG-1) plays a particularly important role in cardiac development. As a ligand of the ErbB family tyrosine kinase receptor, NRG-1 directly binds to membrane-bound ErbB3 or ErbB4, inducing dimerization to produce ErbB2 / ErbB4, ErbB2 / ErbB3, ErbB3 / ErbB3 and ErbB4 / ErbB4 complexes, as well as subsequent intracellular signal transduction. In animal models, the expression of NRG induces paracrine signal transduction to promote the growth and differentiation of cardiac tissue during embryonic development, and the absence of any of ErbB2, ErbB4 or NRG-1 will lead to embryonic death. Furthermore, cancer therapies that block ErbB2 receptor signaling have been shown to have significant cardiotoxic side effects, suggesting that in humans ErbB2-mediated signaling is critical not only for development but also for homeostasis of healthy cardiac tissue.
[0004] Evidence also suggests that NRG-1 signaling plays a role in the development and function of other organ systems and in the pathogenesis of human diseases, including schizophrenia and head and neck cancer. NRG-1 has many isoforms. Studies of mutant mice (knockout mice) have shown that isoforms with different N-terminal regions or EGF-like domains have different functions in vivo. The present invention is based on the NRG-1βa2 isoform.
[0005] Endogenous NRG-1 binds to ErbB3 (HER3) and ErbB4 (HER4) and induces signaling through both. Many preclinical and clinical studies have shown the therapeutic potential of NRG-1 in various cardiovascular indications, primarily through its interaction with ErbB4 (HER4) expressed by cardiomyocytes. However, three key factors limit the clinical application and utility of recombinant human NRG-1 (rhNRG-1). First, NRG-1 signaling through HER3 may promote the development and / or progression of cancer, raising significant concerns for any application requiring long-term dosing or in the absence of severe cardiovascular (CV) risk factors. Second, overactivation of HER3 by NRG-1 may disrupt gastrointestinal (GI) epithelial integrity and homeostasis, leading to severe GI toxicity, thereby losing the therapeutic window of NRG-1. Third, both clinical-stage active protein fragments of rhNRG-1 display short half-lives, suggesting that onerous dosing and dosing regimens may be required to achieve the desired therapeutic exposure levels. Therefore, there is a need to provide NRG-1-based therapeutics that maintain clinically significant therapeutic potential in various cardiovascular indications but have a lower risk of causing or promoting cancer progression, better GI tolerability, and more favorable pharmacokinetic (PK) profiles.
[0006] The present invention addresses these needs by providing a recombinant protein comprising a fusion of the active domain of rhNRG-1 and a HER3-specific antagonist antibody: HER3 signaling is blocked in a manner that mitigates the carcinogenic risk and GI toxicity of rhNRG-1, while the antibody backbone format confers the molecular half-life of a typical monoclonal antibody, making the product more convenient to administer and apply. Summary of the invention
[0007] The present invention provides a method of treating atrial fibrillation and / or cardiac fibrosis in a subject, comprising administering to the subject a recombinant fusion protein comprising a neuregulin-1 (NRG-1) fragment fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb). In some embodiments, cardiac fibrosis comprises atrial fibrosis.
[0008] The present invention provides a method of treating atrial fibrillation in a subject comprising administering to the subject a recombinant fusion protein comprising a neuregulin-1 (NRG-1) fragment fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb). In some embodiments, atrial fibrillation is associated with atrial fibrosis.
[0009] The present invention provides a method of treating atrial fibrosis in a subject comprising administering to the subject a recombinant fusion protein comprising a neuregulin-1 (NRG-1) fragment fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb).
[0010] The present invention provides a recombinant fusion protein comprising a neuregulin-1 (NRG-1) fragment fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb) for use in a method for treating atrial fibrillation and / or cardiac fibrosis. In some embodiments, cardiac fibrosis comprises atrial fibrosis.
[0011] In some embodiments of the methods or recombinant fusion proteins used in the present invention, the NRG-1 fragment comprises an active domain of NRG-1. In some embodiments, the NRG-1 fragment comprises an ERBB3 / 4 binding domain. In some embodiments, the NRG-1 fragment binds to ErbB4 (HER4) and induces signal transduction therethrough. In some embodiments, the mAb inhibits NRG-1 signal transduction via ErbB3 (HER3). In some embodiments, the NRG-1 fragment comprises an NRG-1β2a isoform.
[0012] In some embodiments of the methods or recombinant fusion proteins used in the present invention, the NRG-1 fragment is fused to the C-terminus of the antibody heavy chain via its N-terminal amino acid using a linker. In some embodiments, the linker comprises at least one copy of the Gly-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser linker shown in SEQ ID NO:5. In some embodiments, the C-terminus of the antibody heavy chain comprises the Fc domain of the antibody. In some embodiments, the monoclonal antibody is glycosylated.
[0013] In some embodiments of the methods or recombinant fusion proteins used in the present invention, the NRG-1 fragment comprises the amino acid sequence of SEQ ID NO: 4. In some embodiments, the mAb comprises the heavy chain amino acid sequence of SEQ ID NO: 2. In some embodiments, the mAb comprises the light chain amino acid sequence of SEQ ID NO: 3. In some embodiments, the mAb comprises a substitution mutation in at least one of amino acids 234, 239, and 434 of SEQ ID NO: 2. In some embodiments, at least one substitution mutation comprises an L234F mutation, an S239A mutation, an N434A mutation, or a combination thereof. In some embodiments, the recombinant fusion protein comprises the amino acid sequences of SEQ ID NO: 3 and SEQ ID NO: 14.
[0014] In some embodiments of the methods or recombinant fusion proteins used in the present invention, the recombinant fusion protein promotes HER2 / 4 signaling over HER2 / 3 signaling relative to the signal induction potential of recombinant NRG-1. In some embodiments, the recombinant fusion protein promotes proliferation, differentiation and survival of cardiomyocytes or cardiac tissue in a subject. In some embodiments, the recombinant fusion protein attenuates the proliferation of tumor or cancer cells relative to recombinant NRG-1.
[0015] In some embodiments of the methods or recombinant fusion proteins used in the present invention, the administration of the recombinant fusion protein reduces the duration of atrial fibrillation episodes, or reduces the frequency of atrial fibrillation. In some embodiments, the administration of the recombinant fusion protein reduces the signs or symptoms of atrial fibrillation or atrial fibrosis. In some embodiments, the symptoms of atrial fibrillation include irregular heartbeat, palpitations, dizziness, extreme fatigue, shortness of breath, chest pain, or a combination thereof. In some embodiments, the signs of atrial fibrosis include collagen deposition, and the administration of the recombinant fusion protein reduces collagen deposition in atrial tissue.
[0016] In some embodiments, NRG-1 binds to and induces signaling through ErbB4 (HER4). In some embodiments, the mAb inhibits NRG-1 signaling through ErbB3 (HER3).
[0017] The present invention provides a medicine kit, which comprises an effective amount of the recombinant fusion protein of the present invention or a pharmaceutical composition comprising the recombinant fusion protein of the present invention.
[0018] The present invention provides a recombinant fusion protein, which comprises a neuregulin-1 (NRG-1) fragment fused with a monospecific ErbB3 (HER3) monoclonal antibody (mAb), and is used for manufacturing a drug for treating atrial fibrillation and / or cardiac fibrosis.
[0019] Other features and advantages of the present invention will be apparent from the examples and drawings described in detail below. However, it should be understood that although the detailed description and specific examples indicate embodiments of the present invention, they are given by way of illustration only, because various changes and modifications within the spirit and scope of the present invention will be apparent to those skilled in the art from this detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Various objects and advantages of the present invention and a more complete understanding will become apparent and more readily appreciated by referring to the following detailed description and appended claims taken in conjunction with the accompanying drawings, in which:
[0021] Figure 1 The construction of the expression plasmid used to express the recombinant fusion protein disclosed in the present invention is shown.
[0022] Figure 2A A molecular schematic diagram showing the anti-HER3 mAb / NRG-1 fusion protein of the present invention.
[0023] Figure 2B Representative data generated by SDS-PAGE analysis are shown.
[0024] Figure 2C Shown are the results of Western blots detected by a primary antibody specific for a 61 amino acid active fragment of NRG-1 containing the HER3 / 4 binding domain ("NRG-1", R&D Systems, Minneapolis, MN).
[0025] Figure 2D Shown are the results of Western blots detected by primary antibodies specific for IgG.
[0026] Figure 3 Binding analysis is shown, showing that the recombinant fusion protein disclosed in the present invention binds to the HER3 protein (curve 1, step 2) and can simultaneously bind to the anti-NRG-1 antibody (curve 1, step 3). Please note that the Fc mutation is introduced into the recombinant fusion protein disclosed in the present invention to knock out the Fc effector function of the parent antibody sequence encoding the HER3-specific antibody, thereby reducing the undesirable cytotoxicity to normal tissues expressing the HER3 receptor.
[0027] Figures 4A to 4D Representative graphs showing the mean relative growth rate ± SEM (n=3) of different cancer cell lines treated with anti-HER3 mAb / NRG-1 fusion protein or control are shown. Figure 4A Shown are the average relative growth rates of the NCI-N87 gastric cancer cell line. Figure 4B Shown are the average relative growth rates of the MCF-7 breast cancer cell line. Figure 4C Shown are the average relative growth rates of the RT-112 bladder cancer cell line. Figure 4D The average relative growth rate of T47D breast cancer cell line is shown. Compared with the control NRG-1 peptide and GP120 mAb / NRG-1 fusion protein, the recombinant fusion protein provided by the present invention exhibits significantly lower activity in promoting cancer cell proliferation.
[0028] Figures 5A to 5B It was shown that despite the reduced cancer cell growth potential, the recombinant fusion protein provided by the present invention fully retained the ability to induce PI3K / AKT signaling in cardiomyocytes - showing comparable activity to recombinant NRG-1 and GP120 mAb / NRG-1 fusion protein. Figure 5AThe figure shows the relative ratio of phospho-AKT (pAKT) to total AKT (tAKT) and antibody concentration (in nM) in human cardiomyocytes treated with the recombinant fusion protein of the present invention and control. Figure 5B Western blot analysis of AKT phosphorylation in human cardiomyocytes treated with the recombinant fusion protein of the present invention and controls.
[0029] Figures 6A to 6C Shown is a direct comparison of HER2 / 4 and HER2 / 3 dimerization in the presence of the recombinant fusion proteins disclosed herein and controls. Fig. 6A The assay principle for detecting ligand-induced dimerization is shown. The PathHunter Dimerization Assay developed by Eurofins DiscoverX (Fremont, CA) is used to detect ligand-induced dimerization of the two subunits of the receptor-dimer pair. The β-gal enzyme is divided into two fragments, ProLink (PK) and enzyme receptor (EA). Cells are engineered to co-express target protein 1 fused to the enzyme donor PK and target protein 2 fused to the enzyme receptor EA. Binding of a ligand to one target protein induces its interaction with the other target protein, forcing the two enzyme fragments to complement each other and resulting in the enzyme reaction releasing a chemiluminescent signal, which is detected in relative fluorescence units or RFU. Figure 6B The figure shows that the recombinant fusion protein provided by the present invention can induce HER2 / HER4 dimerization with comparable potency as NRG-1. Figure 6C The figure shows that the potency of the recombinant fusion protein provided by the present invention in inducing HER2 / HER3 dimerization is significantly lower than that of NRG-1. These findings further verify that the recombinant fusion protein provided by the present invention retains the full HER2 / 4 signaling potential of NRG-1 while significantly reducing HER2 / 3 signaling induction.
[0030] Figure 7 The binding affinity of the anti-HER3 mAb / NRG-1 fusion protein of the present invention to HER3 antigens of different species including humans, monkeys, rats and mice was shown. The equilibrium dissociation rates (KD) determined by BIAcore analysis were 3.13×10 -10 (Human), 3.97×10 -10 (Monkey), 2.68×10 -9 (rat) and 2.77×10 -9 (Mouse). These data indicate that the recombinant fusion protein of the present invention has similar binding affinity to human and monkey HER3, while its affinity to rodent (rat and mouse) HER3 is reduced by approximately one order of magnitude.
[0031] Figure 8The graph shows the effect of the recombinant fusion protein on ejection fraction (EF) in a rat model of systolic heart failure induced by coronary artery ligation.
[0032] Figures 9A to 9F Figure 1 is a series of 6 images showing histopathological changes in myocardial structure in a rat model of systolic heart failure induced by coronary artery ligation. Heart tissues near the surgical site were collected and fixed in 4% formaldehyde, and then paraffin sections were prepared and stained with H&E. Fig.9A Heart tissue from sham-operated control rats is shown. Fig. 9B Shown are cardiac tissues from systolic heart failure model rats treated with vehicle control. Fig. 9C Shown are heart tissues of systolic heart failure model rats treated with GP120 mAb / NRG-1 (10 mg / kg). Fig.9D Shown are heart tissues of systolic heart failure model rats treated with anti-HER3 mAb / NRG-1 (1 mg / kg). Fig.9E Shown are heart tissues of systolic heart failure model rats treated with anti-HER3 mAb / NRG-1 (3 mg / kg). Fig.9F Shown are heart tissues of systolic heart failure model rats treated with anti-HER3 mAb / NRG-1 (10 mg / kg).
[0033] Fig.10 Figure 2 is a graph showing the evaluation of in vivo antitumor activity using a NOD / SCID mouse subcutaneous FaDu cancer xenograft model.
[0034] Fig.11 The figure shows the changes in body weight of tumor-bearing mice treated with the recombinant fusion protein of the present invention and the control.
[0035] Fig.12 is a graph showing the pharmacokinetic profile of the recombinant fusion protein in cynomolgus monkeys (Macaca mulatta).
[0036] Fig.13A Shown is a diagram depicting fibrosis analysis of in vitro induced fibrosis in rat atrial tissue samples.
[0037] Fig. 13B Show description in Fig.13A Graph of induction of type I collagen in the absence of an exemplary NRG-1 / HER3 antibody fusion protein in an assay described in . The x-axis depicts the sampling day. The y-axis depicts mRNA expression of type I collagen (type I collagen alpha 1 chain or Col1a1, mRNA), expressed as the fold change of Col1a1 mRNA present compared to the level of Col1a1 mRNA present on day 1 of the assay.
[0038] Fig. 13CShow description in Fig.13A Graph of induction of type III collagen in the absence of an exemplary NRG-1 / HER3 antibody fusion protein in an assay described in . The x-axis depicts the sampling day. The y-axis depicts mRNA expression of type III collagen (type III collagen alpha chain 1 or Col3a1i, mRNA), expressed as the fold change of Col3a1 mRNA present compared to the level of Col3a1 mRNA present on day 1 of the assay.
[0039] Fig.14A Show description in Fig.13A Graph of the effect of NRG-1 / HER3 antibody fusion protein (NRG-1 / HER3) on type I collagen induction in the assay described in . The x-axis depicts the sampling day. The y-axis depicts the mRNA expression of type I collagen in the absence of NRG-1 / HER3, expressed as the fold change of Col1a1 mRNA present compared to the Col1a1 mRNA level present on day 2 of the assay.
[0040] Fig. 14B Show description in Fig.13A Graph of the effect of NRG-1 / HER3 antibody fusion protein (NRG-1 / HER3) on type III collagen induction in the assay described in . The x-axis depicts the sampling day. The y-axis depicts the mRNA expression of type III collagen in the absence of NRG-1 / HER3, expressed as the fold change of Col3a1 mRNA present compared to the Col3a1 mRNA level present on day 2 of the assay.
[0041] Fig.15 Show description in Fig.16 and Fig.18 Figure 2. Atrial fibrillation (AF) induction measured using programmed electrical stimulation (PES) delivered via a transjugular octopole catheter in the in vivo experimental model described in.
[0042] Fig.16 Shown is a graph depicting the measurement of atrial fibrillation in vivo using angiotensin II (Ang-II)-induced hypertensive mouse model.
[0043] Fig.17A Display description of NRG-1 / HER3 antibody fusion protein Fig.16 Graph of the effect of total AF duration in the described models. The x-axis depicts the treatment conditions: CTRL, sham control; ANG II+vehicle, vehicle only control, ANG II+NRG-1 / HER3, animals with ANG II-induced hypertension treated with NRG-1 / HER3 antibody fusion protein. The y-axis depicts the time in seconds (s).
[0044] Fig. 17B Display description of NRG-1 / HER3 antibody fusion protein Fig.16 Graph of the effects of AF induction in the described models. The x-axis depicts the treatment. The y-axis depicts the percentage of mice with AF.
[0045] Fig.18 Shown is a diagram depicting a second atrial fibrillation (AF) model in which mice are fed a high fat diet.
[0046] Fig.19A Show Description Fig.18 Figure 2. Graph of body weight over time for the three groups of mice in the described model. The x-axis depicts time in weeks (W). The y-axis depicts body weight. CRTL: mice not fed a high-fat diet and treated with vehicle alone control; HFD+Vehicle: mice fed a high-fat diet and treated with vehicle alone control; HFD+NRG-1 / HER3, mice fed a high-fat diet and treated with NRG-1 / HER3 antibody fusion protein.
[0047] Fig.19B Display description of NRG-1 / HER3 antibody fusion protein Fig.18 Plot of the effect of total body weight over time on the described metabolic syndrome model. The x-axis depicts time in weeks (W). The y-axis depicts the change in body weight.
[0048] Fig.19C Display description of NRG-1 / HER3 antibody fusion protein Fig.18 Graph of the effect of glucose tolerance in the described model. The x-axis depicts the time after injection of 20% glucose. The y-axis depicts the blood glucose concentration in mg / dL.
[0049] Fig. 20A Display description of NRG-1 / HER3 antibody fusion protein Fig.18 Graph of the effect of total duration of irregular atrial arrhythmias in the described metabolic syndrome model. The x-axis depicts the treatment conditions: WT, wild type, no high fat diet and vehicle only injection; HFD+vehicle: mice fed a high fat diet and controlled with vehicle alone; HFD+NRG-1 / HER3, mice fed a high fat diet and treated with NRG-1 / HER3 antibody fusion protein. The y-axis depicts time in seconds (s).
[0050] Fig. 20B Display description of NRG-1 / HER3 antibody fusion protein Fig.18Figure 2. Effects of arrhythmia induction in the described metabolic syndrome model. The x-axis depicts the treatment conditions: CRTL: mice not fed a high-fat diet and treated with vehicle alone control; HFD+Vehicle: mice fed a high-fat diet and treated with vehicle alone control; HFD+NRG-1 / HER3, mice fed a high-fat diet and treated with NRG-1 / HER3 antibody fusion protein. The y-axis depicts the percentage of mice with induced AF.
[0051] Figures 21A to 21F 1 is a series of images showing collagen I immunohistochemical staining of cardiac tissue from rats with systolic heart failure (or heart failure with reduced ejection fraction, HFrEF) model (Example 7). Rats were sham operated ( Fig.21A ) or surgery and solvent alone ( Fig.21B )、GP120-NRG-1 antibody fusion protein ( Fig. 21C )、1mg / kg NRG-1 / HER3 antibody fusion protein ( Fig.21D )、3mg / kg NRG-1 / HER3 antibody fusion protein ( Fig.21E ) or 10mg / kg NRG-1 / HER3 antibody fusion protein ( Fig.21F )deal with.
[0052] Fig. 22 Figure 2 is a diagram showing the experimental design for testing the effect of NRG-1 / HER3 antibody fusion protein in the Aachener minipig model of hypertension and atrial fibrosis induced by deoxycorticosterone acetate (aldosterone agonist).
[0053] Fig.23 A pair of electrocardiograms (ECGs) from a DOCA model minipig and an equation are shown. The top ECG is a representative ECG of atrial fibrillation induced by 50 Hz burst pacing. The bottom ECG is a representative ECG of atrial fibrillation not induced by 50 Hz burst pacing. The equation shows how the ECG data is used to calculate atrial fibrillation induction.
[0054] Fig.24 Graph showing mean atrial pressure (in mmHg, y-axis) for control, DOCA+Vehicle (VEH), and DOCA+NRG-1 / HER3 minipigs.
[0055] Fig.25 Figure 2 shows atrial fibrillation (AF) induction in control, DOCA+vehicle, and DOCA+NRG-1 / HER3 minipigs. AF inducibility was calculated as Fig.23 as shown in .
[0056] Fig.26Figure 1 shows the extent of atrial fibrosis in control, DOCA+vehicle, and DOCA+NRG-1 / HER3 minipigs (left) and three representative images (right). DETAILED DESCRIPTION
[0057] The present invention utilizes a recombinant fusion protein, which comprises a fusion product of a monoclonal antibody and an active fragment of a neuregulin-1 protein isoform, and is suitable for a variety of cardiovascular and central nervous system (CNS) indications. definition
[0058] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0059] For purposes of interpreting this specification, the following definitions shall apply and, wherever appropriate, terms used in the singular shall also include the plural and vice versa. In the event of a conflict between any of the following definitions and any document incorporated herein by reference, the following definitions shall prevail.
[0060] "Neuregulin or neuregulin analogs" are molecules that can activate ErbB2 / ErbB4 or ErbB2 / ErbB3 heterodimeric protein tyrosine kinases, such as all neuregulin isoforms, individual neuregulin EGF domains, neuregulin mutants, and any type of neuregulin-like gene products that also activate the above receptors. Preferred "neuregulin" used in the present invention is a polypeptide fragment of a human neuregulin 1β2 isoform containing an EGF-like domain and a receptor binding domain. In one embodiment, the neuregulin fragment is an active fragment. Neuregulin-1 (NRG-1) and its isoforms are also known in the art as neuregulin 1 (NRG1), glial growth factor (GGF), Heregulin (HGL), HRG, new differentiation factor (NDF), ARIA, GGF2, HRG1, HRGA, SMDF, MST131, MSTP131, and NRG1 intron transcript 2 (NRG1-IT2).
[0061] The terms "ErbB3", "ErbB3 (HER3)", "HER3" refer to the same protein (or, when referred to, the same gene) and are used interchangeably in the present invention. In some embodiments, the recombinant fusion comprises a monoclonal antibody portion that is specific for ErbB3. ErbB3 (erb-b2 receptor tyrosine kinase 3) is also known in the art as FERLK, LCCS2, ErbB-3, c-erbB3, erbB3-S, MDA-BF-1, c-erbB-3, p180-ErbB3, p45-sErbB3, and p85-sErbB3.
[0062] In one embodiment, the terms "ErbB4", "ErbB4 (HER4)", "HER4" refer to the same protein (or the same gene when mentioned) and are used interchangeably in the present invention. ErbB4 (erb-b2 receptor tyrosine kinase 4) is also known in the art as ALS19 and p180erbB4.
[0063] In one embodiment, the terms "ErbB2", "ErbB2 (HER2)", "HER2" refer to the same protein (or, when referred to, the same gene) and are used interchangeably in the present invention. ErbB2 (erb-b2 receptor tyrosine kinase 2) is also known in the art as NEU, NGL, TKR1, CD340, HER-2, MLN 19, and HER-2 / neu.
[0064] As used herein, the term "activity" refers to a fragment having biological activity or biological function. In some embodiments, the activity is equal to or close to the activity of the wild-type protein.
[0065] As used herein, the term "subject" includes, but is not limited to, mammals, including, for example, humans, non-human primates (e.g., monkeys), mice, pigs, cows, goats, rabbits, rats, guinea pigs, hamsters, horses, monkeys, sheep, or other non-human mammals; non-mammals, including, for example, non-mammalian vertebrates, such as birds (e.g., chickens or ducks) or fish; and non-mammalian invertebrates. In some embodiments, the methods and compositions of the present invention are used to treat (preventatively and / or therapeutically) non-human animals. The term "subject" may also refer to a patient, i.e., an individual awaiting or receiving medical care.
[0066] The term "pharmaceutical composition" in the present invention refers to a composition suitable for medical use in a subject (including an animal or a human). A pharmaceutical composition generally comprises an effective amount of an active agent (e.g., a recombinant fusion protein of the present invention) and a pharmaceutically acceptable carrier, diluent or excipient (e.g., a buffer, an adjuvant or the like).
[0067] The term "effective amount" refers to a dose or amount sufficient to produce the desired result. The desired result may include an objective or subjective improvement in the recipient of the dose or amount (e.g., long-term survival, reduction in the number and / or size of tumors, effective prevention of a disease state, etc.).
[0068] "Prophylactic treatment" is a treatment administered to a subject who does not show signs or symptoms of a disease, pathology, or medical condition, or who only shows early signs or symptoms of a disease, pathology, or medical condition, such that the treatment is administered for the purpose of reducing, preventing, or reducing the risk of developing a disease, pathology, or medical condition. Prophylactic treatment acts as a prophylactic treatment for a disease or condition. "Prophylactic activity" is the activity of an agent (such as a recombinant fusion protein of the present invention, or a composition thereof) that, when administered to a subject who does not show signs or symptoms of a pathology, disease, or condition (or who only shows early signs or symptoms of a pathology, disease, or condition), reduces, prevents, or reduces the risk of a subject developing a pathology, disease, or condition. A "prophylactically useful" agent or compound (e.g., a recombinant fusion protein of the present invention) refers to an agent or compound that can be used to reduce, prevent, treat, or reduce the development of a pathology, disease, or condition.
[0069] "Therapeutic treatment" is a treatment administered to a subject who exhibits symptoms or signs of a pathology, disease, or condition, wherein the purpose of administering the treatment to the subject is to reduce or eliminate these signs or symptoms of the pathology, disease, or condition. "Therapeutically active" is the activity of an agent (such as a recombinant fusion protein of the invention or a composition thereof) that, when administered to a subject suffering from signs or symptoms of a pathology, disease, or condition, eliminates or alleviates such signs or symptoms. A "therapeutically useful" agent or compound (e.g., a recombinant fusion protein of the invention) indicates that the agent or compound can be used to reduce, treat, or eliminate such signs or symptoms of a pathology, disease, or condition.
[0070] Unless otherwise indicated, as used herein, the term "treating cancer" refers to partially or completely reversing, alleviating, inhibiting the progression of, or preventing a subject's tumor growth, tumor metastasis, or other carcinogenic or tumor cells. Unless otherwise indicated, as used herein, the term "treating" refers to the act of treating.
[0071] Unless otherwise indicated, as used in the present invention, the term "treating cardiovascular disease" refers to partially or completely preventing, inhibiting, curbing, delaying, reversing or alleviating the onset of a subject's cardiovascular disease or condition, or the progression of a subject's pre-existing cardiovascular disease or condition or its symptoms. Non-limiting examples of cardiovascular diseases that can be treated by the methods of the present invention include chronic heart failure / congestive heart failure (CHF), acute heart failure / myocardial infarction (MI), left ventricular systolic dysfunction, reperfusion injury associated with MI, chemotherapy-induced cardiotoxicity (adult or child), radiation-induced cardiotoxicity, adjuvant therapy for surgical intervention of congenital heart disease in children, and atrial fibrosis. Non-limiting examples of cardiovascular disease symptoms include shortness of breath, cough, rapid weight gain, swelling of the legs, ankles and abdomen, dizziness, fatigue, weakness, vertigo, chest pain, fainting (syncope), tachycardia, bradycardia and arrhythmia, such as atrial fibrillation. The method for determining the progression of cardiovascular disease and the effectiveness of treatment is obvious to those of ordinary skill in the art. For example, the progression of various cardiovascular diseases can be determined by ejection fraction, electrocardiogram (ECG), Holter, echocardiogram, stress test, cardiac catheterization, cardiac computed tomography (CT) scan, and cardiac magnetic resonance imaging (MRI).
[0072] As used herein, "fibrosis" refers to the inappropriate formation and deposition of extracellular matrix (ECM) components such as collagen. ECM usually surrounds parenchymal cells and supports their migration, differentiation, proliferation and normal function. Fibrotic ECM can impair tissue homeostasis and may cause organ dysfunction due to loss of structural integrity and abnormal remodeling. Fibrosis is characterized by the proliferation of fibroblasts, which can differentiate into myofibroblasts that secrete ECM proteins. "Cardiac fibrosis" generally refers to fibrosis of the heart, and includes atrial fibrosis, as well as fibrosis affecting other areas of the heart, such as but not limited to the ventricles, myocardium, pericardium, endocardium and valves.
[0073] In the heart, replacement or reparative fibrosis occurs after cardiac injury and is associated with cardiomyocyte death and replacement of necrotic myocardial areas with fibrotic scar tissue. In reactive fibrosis, deposition of collagen and other ECM proteins in the interstitial space surrounding cardiac cells and blood vessels increases, leading to enlargement of this space without replacement of injured or dead cardiomyocytes.
[0074] As used in the present invention, "atrial fibrosis" refers to fibrosis of the atrium. Atrial fibrosis is closely related to atrial fibrillation (AF), which is one of the most common arrhythmias in humans. Without wishing to be bound by theory, it is believed that atrial fibrosis can cause abnormal electrical conduction through the atrium, thereby causing atrial fibrillation. Fibrosis can be detected by any suitable means known in the art, including but not limited to DE-MR imaging (MRI), circulating biomarkers (e.g., prolactin-3, MMP-3, MMP-9, high-sensitivity cardiac troponin T, osteopontin, inhibition of tumorigenicity 2, connective tissue growth factor (CTGF), resistin (RETN), periostin and mid-segment atrial natriuretic peptide precursor, and microRNA, such as miRNA-15, miR-21, miR-29c, miR-328, miR-30a, miR-214, miR-503 and miR-133a) and electroanatomical voltage maps.
[0075] As used herein, "arrhythmia" refers to an irregular heartbeat and includes tachycardia (abnormally fast heartbeat) and bradycardia (abnormally slow heartbeat). Atrial fibrillation (AF) is an irregular and usually very fast heart rhythm that can lead to blood clots in the heart. In AF, the normal beats of the atria are irregular, obstructing the flow of blood from the atria to the ventricles. AF can be acute or chronic. AF can be assessed based on the duration of the AF episode and the number of episodes that occur in a given unit of time (e.g., AF / episode / day, week, or month). Paroxysmal AF begins suddenly and ends spontaneously within 7 days. In contrast, persistent AF occurs for more than 7 days and ends spontaneously or with treatment. Long-term persistent AF refers to uninterrupted AF for more than one year. Permanent AF refers to AF that persists despite treatment to restore normal sinus rhythm. Symptoms of AF include irregular heartbeat, palpitations, dizziness, extreme fatigue, shortness of breath, and chest pain.
[0076] Unless otherwise indicated, as used herein, the term "treating a central nervous system (CNS)-related disease" refers to a method of partially or completely preventing, inhibiting, suppressing, delaying, reversing or alleviating the onset of a CNS-related disease or condition in a subject. The term "treating a CNS-related disease" may also refer to reversing, slowing down or otherwise alleviating a pre-existing CNS-related disease or condition or a symptom thereof. Exemplary but non-limiting examples of CNS-related diseases or conditions that can be treated with the methods of the present invention include amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's Disease, Bell's Palsy, epilepsy and epileptic seizures, Guillain-Barre Syndrome, stroke, traumatic brain injury, multiple sclerosis, or a combination. Treatment of CNS-related disorders can improve or prevent symptoms such as tremors, bradykinesia, muscle rigidity, loss of balance, impaired posture, speech changes, loss of motor control, paralysis, difficulty swallowing, muscle spasms, seizures, memory loss, and confusion.
[0077] The term "identical" or "percent identity" in the context of two or more nucleic acid or polypeptide sequences refers to two or more sequences or subsequences that are identical or have a specific percentage of nucleotides or amino acid residues that are identical when compared and aligned for maximum correspondence. In order to determine the percent identity, the sequences are aligned for optimal comparison purposes (for example, a gap can be introduced into the sequence of the first amino acid or nucleic acid sequence for optimal alignment with the second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions / total number of positions (e.g., overlapping positions) × 100). In some embodiments, the two sequences are the same length.
[0078] The term "substantially identical" in the context of two nucleic acids or polypeptides refers to two or more sequences or subsequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% identical, or at least 99% identical (e.g., as determined using one of the methods described below).
[0079] As used herein, the terms "binding", "specifically binding to" or "specificity" refer to a measurable and reproducible interaction, such as binding between a target and an antibody, which determines the presence of the target in the presence of a heterogeneous population of molecules, including biomolecules. For example, an antibody that specifically binds to a target (which may be an epitope) is an antibody that binds to this target with greater affinity, avidity, more readily and / or for a longer duration than it binds to other targets. In one embodiment, the extent of binding of the antibody to an unrelated target is less than about 10% of the binding of the antibody to the target, for example as measured by radioimmunoassay (RIA). In certain embodiments, the dissociation constant (Kd) of an antibody that specifically binds to a target is <1 μM, <100 nM, <10 nM, <1 nM or <0.1 nM.
[0080] In certain embodiments, an antibody specifically binds to an epitope on a protein that is conserved between proteins from different species. In another embodiment, specific binding may include but does not require exclusive binding.
[0081] As used in this specification, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a neuregulin" or "a neuregulin peptide" includes mixtures of such neuregulins, neuregulin isoforms, and / or neuregulin-like polypeptides. Reference to a "formulation" or "method" includes one or more formulations, methods, and / or steps of the type described herein, and / or formulations, methods, and / or steps that will become apparent to one skilled in the art upon reading this disclosure.
[0082] The term "polypeptide" refers to a polymer of amino acids and their equivalents, rather than a specific length of the product; therefore, "peptide" and "protein" are included in the definition of polypeptide. The definition of polypeptide also includes "antibodies" as defined in the present invention. "Polypeptide region" refers to a fragment of a polypeptide, which may contain, for example, one or more domains or motifs (for example, a polypeptide region of an antibody may contain, for example, one or more complementarity determining regions (CDRs)). The term "fragment" refers to a portion of a polypeptide, preferably having at least 20 consecutive or at least 50 consecutive amino acids of a polypeptide.
[0083] Unless the context indicates otherwise, a "derivative" is a polypeptide or fragment thereof (also referred to as a "variant") having one or more non-conservative or conservative amino acid substitutions relative to a second polypeptide; or a polypeptide or fragment thereof modified by covalent attachment to a second molecule, such as by attachment to a heterologous polypeptide, or by glycosylation, acetylation, phosphorylation, and the like. Further included in the definition of "derivative" are, for example, polypeptides containing one or more amino acid analogs (e.g., non-natural amino acids and their analogs), polypeptides with unsubstituted bonds, and other modified polypeptides known in the art, both naturally and non-naturally occurring.
[0084] An "isolated" polypeptide is one that has been identified and separated and / or recovered from components of its natural environment. Contaminating components of its natural environment are substances that interfere with the diagnostic or therapeutic use of the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. Isolated polypeptides include isolated antibodies or fragments or derivatives thereof.
[0085] As used herein, the term "about" in relation to a quantity refers to plus or minus 5%, or in another embodiment, plus or minus 10%, or in another embodiment, plus or minus 15%, or in another embodiment, plus or minus 20%.
[0086] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of disclosing and describing the materials on which the references are based. Recombinant fusion protein-antibody
[0087] The present invention utilizes a recombinant fusion protein comprising a monoclonal antibody fused to a fragment of a neuregulin-1 protein isoform for use in a variety of cardiovascular and neurological indications. In typical embodiments, the antibody is specific for ERBB3 (HER3).
[0088] As used herein, "antibody" refers to a protein comprising one or more polypeptides that are substantially or partially encoded by immunoglobulin genes or fragments of immunoglobulin genes. Recognized immunoglobulin genes include κ, λ, α, γ, δ, ε and μ constant region genes, as well as numerous immunoglobulin variable region genes. Light chains are classified as κ or λ. Heavy chains are classified as γ, μ, α, δ or ε, which in turn define the immunoglobulin classes IgG, IgM, IgA, IgD and IgE, respectively. Typical immunoglobulin (e.g., antibody) structural units include tetramers. Each tetramer is composed of two pairs of identical polypeptide chains, each pair having one "light" chain (about 25 kD) and one "heavy" chain (about 50 -70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids, which is primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light chains and heavy chains, respectively.
[0089] Antibodies exist in the form of complete immunoglobulins, or in the form of many well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests antibodies below the disulfide bonds in the hinge region to produce F(ab')2, i.e., a dimer of Fab, which itself is a light chain joined to VH-CH1 by a disulfide bond. F(ab')2 can be reduced under mild conditions to destroy the disulfide bonds in the hinge region, thereby converting the F(ab')2 dimer into a Fab' monomer. Fab' monomers are essentially Fabs with a portion of the hinge region (see Fundamental Immunology, WE Paul, Raven Press, New York (1999), for a more detailed description of other antibody fragments). Although various antibody fragments are defined based on the digestion of complete antibodies, it will be appreciated by those skilled in the art that such Fab' fragments, etc., can be synthesized de novo chemically or by using recombinant DNA methods. Therefore, as used herein, the term antibody also includes antibody fragments produced by modifying whole antibodies or synthesized de novo using recombinant DNA methods. Antibodies include single chain antibodies, including single chain Fv (sFv or scFv) antibodies, in which the variable heavy chain and the variable light chain are linked together (directly or via a peptide linker) to form a continuous polypeptide. Antibodies include single domain antibodies, which comprise antibody fragments consisting of a single monomeric variable antibody domain capable of selectively binding to an antigenic domain. Exemplary single domain antibodies include VHH fragments, which were originally isolated from camelids.
[0090] The antibody domain of the fusion protein optionally comprises all or a portion of an immunoglobulin molecule, and optionally contains all or a portion of an immunoglobulin variable region (i.e., a region specific for a disease-associated antigen), and optionally comprises regions encoded by V genes and / or D genes and / or J genes.
[0091] As described above (see above definition), the antibodies used in the present invention optionally include F(ab)2, F(ab')2, Fab, Fab', scFv, single domain antibodies, etc., depending on the specific requirements of the embodiment. Some embodiments utilize fusion proteins comprising IgG domains. However, other embodiments include alternative immunoglobulins, such as IgM, IgA, IgD and IgE. In addition, all possible isotypes of various immunoglobulins are also included in the current embodiment. Therefore, IgG1, IgG2, IgG3, etc. are all possible molecules in the antibody domain of the antibody-immunostimulator fusion protein used in the present invention. In addition to the selection of the type and isotype of immunoglobulins, different embodiments of the present invention include various hinge regions (or their functional equivalents). Such hinge regions provide flexibility between different domains of antibody-immunostimulator fusion proteins. See, for example, Penichet et al. 2001 "Antibody-cytokine fusion proteins for the therapy of cancer" J Immunol Methods 248: 91-101.
[0092] In some embodiments, the mAb comprised by the recombinant fusion protein of the present invention is monospecific for ErbB3 (HER3).
[0093] Human HER3 (ErbB-3, ERBB3, c-erbB-3, c-erbB3, receptor tyrosine protein kinase erbB-3) encodes a member of the receptor tyrosine kinase epidermal growth factor receptor (EGFR) family, which also includes HER1 (also known as EGFR), HER2 and HER4 (Kraus, MH et al., PNAS 86 (1989) 9193-9197; Plowman, GD et al., PNAS 87 (1990) 4905-4909; Kraus, MH et al., PNAS 90 (1993) 2900-2904). Like the prototype epidermal growth factor receptor, the transmembrane receptor HER3 consists of an extracellular ligand binding domain (ECD), a dimerization domain within the ECD, a transmembrane domain, an intracellular protein tyrosine kinase domain (TKD) and a C-terminal phosphorylation domain. This membrane-bound HER3 protein has a Heregulin (HRG) binding domain in the extracellular domain, but no active kinase domain. Therefore, it can bind this ligand, but cannot transmit signals to the cell via protein phosphorylation. However, it does form heterodimers with other HER family members that have kinase activity. Heterodimerization leads to activation of receptor-mediated signaling pathways and transphosphorylation of its intracellular domain. Dimer formation between HER family members expands the signaling potential of HER3, not only as a means of signal diversification, but also as a means of signal amplification. For example, HER2 / HER3 heterodimers induce one of the most important cell division signals via the PI3K and AKT pathways in HER family members (Sliwkowski MX et al., J.Biol.Chem.269 (1994) 14661-14665; Alimandi M et al., Oncogene.10 (1995) 1813-1821; Hellyer, NJ, J.Biol.Chem.276 (2001) 42153-4261; Singer, E., J.Biol.
[0094] In one embodiment, the human ERBB3 protein comprises the following amino acid sequence provided in GenBank AAH02706.1 and set forth in SEQ ID NO: 1:
[0095] MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKAF (SEQ ID NO: 1). It should be understood that the ERBB3 (HER3) sequence targeted by the antibodies of the methods and compositions of the present invention may be an isomer, homolog or variant of SEQ ID NO: 1.
[0096] In one embodiment, the mAb of the recombinant fusion protein provided by the present invention is an anti-Her3 mAb, which inhibits NRG-1 signaling via ErbB3 (HER3).
[0097] In another specific embodiment, the mAb included in the recombinant fusion protein of the present invention includes an anti-HER3 mAb. Such anti-HER3 antibodies and their sequences are known in the art and may include, but are not limited to, the following: patritumab, seribantumab (all-human mAb), LJM716, KTN3379, AV-203, REGN1400, GSK2849330 or MM-141. Such antibodies may also be selected from any of the following forms, including chimeric, bispecific, non-human, all-human or humanized forms, as long as they bind to human ERBB3 (HER3) and inhibit its signal transduction. In some embodiments, the anti-HER3 antibody is humanized.
[0098] In some embodiments, the term "antibody" encompasses various forms of antibody structures, including but not limited to whole antibodies and antibody fragments. The antibody according to the present invention is preferably a human antibody, a humanized antibody, a chimeric antibody or an antibody further genetically engineered, as long as the characteristics of the present invention are retained. "Antibody fragments" comprise a portion of a full-length antibody, preferably its variable domain, or at least its antigen binding site. Examples of antibody fragments include bifunctional antibodies, single-chain antibody molecules and multispecific antibodies formed by antibody fragments. scFv antibodies are described in, for example, Huston, JS, Methods in Enzymol. 203 (1991) 46-88. In addition, antibody fragments comprise single-chain polypeptides having a V H domain characteristics, namely, it can be L domains assembled together, or with V binding to the corresponding antigen L domain characteristics, namely, it can be H The domains assemble together to form a functional antigen binding site, thereby providing the properties of the antibodies according to the invention. As used herein, the terms "monoclonal antibody" or "monoclonal antibody composition" refer to a preparation of antibody molecules of a single amino acid composition.
[0099] In some embodiments, chimeric antibodies can be used in the compositions and methods provided by the present invention. In one embodiment, the term "chimeric antibody" refers to a monoclonal antibody comprising a variable region (i.e., a binding region) from a mouse and at least a portion of a constant region derived from a different source or species, usually prepared by recombinant DNA technology. Chimeric antibodies comprising mouse variable regions and human constant regions are particularly preferred. Such rat / human chimeric antibodies are the expression products of immunoglobulin genes comprising DNA fragments encoding rat immunoglobulin variable regions and DNA fragments encoding human immunoglobulin constant regions. Other forms of "chimeric antibodies" encompassed by the present invention are antibodies whose classes or subclasses have been modified or changed from the original antibodies. Such "chimeric" antibodies are also referred to as "class switching antibodies". Methods for producing chimeric antibodies involve conventional recombinant DNA and gene transfection techniques currently known in the art. See, for example, Morrison, SL et al., Proc. Natl. Acad Sci. USA 81 (1984) 6851-6855; US 5,202,238 and US 5,204,244.
[0100] In one embodiment, humanized antibodies can be used in the compositions and methods provided by the present invention. In some embodiments, the term "humanized antibody" or "humanized form of an antibody" refers to an antibody framework or "complementarity determining region" (CDR) that has been modified to include a CDR of an immunoglobulin with different specificity compared to the parent immunoglobulin. In other embodiments, the CDRs of VH and VL are transplanted into the framework region of a human antibody to prepare a "humanized antibody". See, for example, Riechmann, L. et al., Nature 332 (1988) 323-327; and Neuberger, MS et al., Nature 314 (1985) 268-270. The heavy and light chain variable framework regions may be derived from the same or different human antibody sequences. The human antibody sequence may be a naturally occurring human antibody sequence. Human heavy and light chain variable framework regions are listed, for example, in Lefranc, M.-P., Current Protocols in Immunology (2000) - Appendix IP A.1P.1-A.1P.37 and can be obtained through IMGT, the international ImMunoGeneTics information (http: / / imgt.cines.fr) or obtained via http: / / vbase.mrc-cpe.cam.ac.uk. The framework region may be optionally modified by other mutations. Particularly preferred CDRs correspond to sequences representing the recognition of the antigens mentioned above for chimeric antibodies. As used herein, the term "humanized antibody" also includes such antibodies modified in the constant region to produce the properties according to the present invention, especially in complement component 1q (Clq) binding and / or Fc receptor (FcR) binding, for example, by "class switching", i.e., changes or mutations in the Fc portion (e.g., IgG1 to IgG4 and / or IgG1 / IgG4 mutations). As used herein, the term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies are currently well known in the art (van Dijk, MA and van de Winkel, JG, Curr. Opin. Chem. Biol. 5 (2001) 368-374). Human antibodies can also be produced in transgenic animals (e.g., mice) that are capable of producing a full spectrum or selected human antibodies in the absence of endogenous immunoglobulin production after immunization. Transferring the human germline immunoglobulin gene array into such germline mutant mice will result in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits, A. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 2551-2555; Jakobovits, A. et al., Nature 362 (1993) 255-258; Brueggemann, MD et al., Year Immunol. 7 (1993) 33-40). Human antibodies can also be produced in phage display libraries (Hoogenboom, HR and Winter, G., J. Mol. Biol. 227 (1992) 381-388; Marks, JD et al., J. Mol. Biol. 222 (1991) 581-597). The techniques of Cole, A. et al. and Boerner, P. et al. can also be used to prepare human monoclonal antibodies (Cole, A. et al., Monoclonal Antibodies and Cancer Therapy, Liss, AL, p. 77 (1985); and Boerner, P. et al., J. Immunol. 147 (1991) 86-95). As already mentioned with respect to humanized antibodies according to the present invention, the term "human antibody" as used in the present invention also includes such antibodies that have been modified in the constant region to produce the properties according to the present invention.
[0101] In a specific embodiment of the present invention, the mAb contained in the recombinant fusion protein provided by the present invention comprises at least one mutation in the Fc domain or region.
[0102] As used in the present invention, the term "recombinant human antibody" is intended to include all human antibodies prepared, expressed, produced or isolated by recombinant means, such as antibodies isolated from host cells such as NS0 or CHO cells or from animals (such as mice) of transgenic human immunoglobulin genes, or antibodies expressed using recombinant expression vectors transfected into host cells. Such recombinant human antibodies have variable regions and constant regions in rearranged form. The recombinant human antibodies according to the present invention have undergone in vivo somatic hypermutation. Therefore, the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that may not naturally exist in the human antibody germline library in vivo, although they are derived from and related to human germline VH and VL sequences.
[0103] In some embodiments, the terms "bind to human HER3", "specifically bind to human HER3" or "anti-HER3 antibody" are interchangeable and refer to an antibody that specifically binds to the human HER3 antigen with a KD value of about 4.81× at 25°C. - 10 mol / L or less. Binding affinity is determined at 25°C using standard binding assays such as surface plasmon resonance ( , GE-Healthcare Uppsala, Sweden). Therefore, as used in the present invention, "antibodies that bind to human HER3" refers to antibodies or portions thereof that specifically bind to human HER3 antigens with a binding affinity of KD 1.0×10 -8 mol / L-1.0×10 -13 mol / L, and preferably the KD value at 25°C is 4.81× -10 mol / L or lower.
[0104] In another embodiment, the anti-HER3 antibody included in the recombinant fusion protein disclosed in the present invention comprises a variable region heavy (VH) chain and a variable region light (VL) chain. In one embodiment, the antibody comprises VH and VL sequences of SEQ ID NO: 2 and SEQ ID NO: 3, respectively; and has one or more of the following properties: inhibiting HER3 phosphorylation in tumor cells, inhibiting AKT phosphorylation in tumor cells, inhibiting signal transduction through ErbB3 (HER3), and inhibiting the proliferation of tumor cells.
[0105] In one embodiment, the anti-HER3 mAb provided by the present invention comprises the VH amino acid sequence listed in SEQ ID NO: 2: Heavy Chain: QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE INHSGSTNYNPSLKSRVTIS VETSKNQFSL KLSSVTAADT AVYYCARDKW TWYFDLWGRG TLVTVSSAST KGPSVFPLAPSSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYICNVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APEFLGGPAV FLFPPKPKDT LMISRTPEVT CVVVDVSHEDPEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAKGQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHE ALHAHYTQKS LSLSPGK(SEQ ID NO:2).
[0106] In one embodiment, the anti-HER3 mAb provided by the present invention comprises the VL amino acid sequence of SEQ ID NO:3: light chain: DIEMTQSPDS LAVSLGERAT INCRSSQSVL YSSSNRNYLA WYQQNPGQPP KLLIYWASTRESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYYST PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQLKSGTASVVC LLNNFYPREA KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYACEVTHQGLSSP VTKSFNRGEC(SEQ ID NO:3).
[0107] In one embodiment, the anti-HER3 antibody of the present invention comprises at least one mutation in the Fc region. In another embodiment, the mature anti-HER3 antibody of the present invention (i.e., lacking a signal peptide) comprises at least one mutation in amino acids 234, 239, 434, or a combination thereof, and in other embodiments, the amino acid mutation comprises at least one of the following substitution mutations: L234F, S239A, N434A, or a combination thereof. In another embodiment, the mutation of amino acids 234 and / or 239 reduces the effector function of the anti-HER3 antibody. In another embodiment, the mutation of amino acid 434 extends the half-life of the antibody in a subject.
[0108] In some embodiments, one or more mutations in the Fc region reduce effector function. In some embodiments, the reduced effector function includes a reduced affinity of the anti-HER3 antibody for one or more Fc receptors. FcR can be FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa (158F), FcγRIIIa (158V) and C1q. In some embodiments, the reduced affinity includes an increase in the dissociation constant by about 1 order of magnitude or greater. In some embodiments, the introduction of one or more Fc mutations increases the KD of the anti-HER3 antibody of the fusion protein comprising it to FcγRI from 2.81×10 -9 M increased to 1.03×10 -8 M. In some embodiments, one or more Fc mutations are introduced to increase the KD of the anti-HER3 antibody comprising the fusion protein thereof to FcγRIIa from 3.95×10 -7 M increased to 1.35×10 -6 M. In some embodiments, one or more Fc mutations are introduced to increase the KD of an anti-HER3 antibody comprising a fusion protein thereof to FcγRIIb from 1.03×10 -7 M increased to 1.52×10 -6 M. In some embodiments, the introduction of one or more Fc mutations increases the KD of the anti-HER3 antibody comprising the fusion protein thereof for FcγRIIIa (158F) from 6.37×10 -8 M increased to 1.18×10 -7 M. In some embodiments, the introduction of one or more Fc mutations increases the KD of the anti-HER3 antibody comprising the fusion protein thereof to FcγRIIIa (158V) from 3.41×10 -8 M increased to 9.10×10 -8 M.
[0109] In some embodiments, the anti-HER3 antibody or a recombinant fusion protein comprising the same binds to FcγRI with an equilibrium dissociation constant (KD) greater than or equal to 1.03×10 -8M. In some embodiments, the anti-HER3 antibody or recombinant fusion protein comprising the same comprises one or more Fc mutations and has a kinase activity greater than or equal to 1.35×10 -6 In some embodiments, the anti-HER3 antibody or recombinant fusion protein comprising the same comprises one or more Fc mutations and binds to FcγRIIa with a KD greater than or equal to 1.5×10 -6 In some embodiments, the anti-HER3 antibody or recombinant fusion protein comprising the same comprises one or more Fc mutations and binds to FcγRIIb with a KD of greater than or equal to 1.18×10 -7 The KD of M binds to FcγRIIIa (158F). In some embodiments, the anti-HER3 antibody or recombinant fusion protein comprising the same comprises one or more Fc mutations and has a KD greater than or equal to 9.10×10 -8 The KD of M binds to FcγRIIIa (158V).
[0110] As used herein, the term "antibody effector function" refers to the function contributed by the Fc region of Ig. Such functions can be achieved by, for example, binding of the Fc effector region to an Fc receptor on an immune cell having phagocytic or lytic activity or by binding of the Fc effector region to a component of the complement system.
[0111] In one embodiment, the anti-HER3 antibody does not induce antibody-dependent cellular cytotoxicity (ADCC).The term "antibody-dependent cellular cytotoxicity (ADCC)" refers to the lysis of human target cells by an antibody according to the present invention in the presence of effector cells.
[0112] In one embodiment of the invention, the antibody according to the invention is glycosylated. In some embodiments, the glycosylation is N-glycosylation. In other embodiments, the glycosylation is O-glycosylation.
[0113] In the context of the recombinant fusion protein provided by the present invention and according to the present invention, the antibody contained in the recombinant fusion protein can be produced via recombinant means. Such methods are widely known in the prior art and include expressing proteins in prokaryotic and eukaryotic cells, followed by separation of antibody polypeptides and generally purification to a pharmaceutically acceptable purity. For protein expression, nucleic acids encoding light and heavy chains or fragments thereof are inserted into expression vectors by standard methods. Expressed in appropriate prokaryotic or eukaryotic host cells, such as CHO cells, NS0 cells, SP2 / 0 cells, HEK293 cells, COS cells, yeast or Escherichia coli cells, and antibodies are recovered from cells (after supernatant or cell lysis). Recombinant production of antibodies is well known in the art and is described in, for example, review articles Makrides, SC, Protein Expr. Purif. 17 (1999) 183-202; Geisse, S. et al., Protein Expr. Purif. 8 (1996) 271-282; Kaufman, RJ, Mol. Biotechnol. 16 (2000) 151-161; Werner, RG, Drug Res. 48 (1998) 870-880. The antibodies may be present in whole cells, cell lysates, or in partially purified or substantially purified form. Purification is performed to eliminate other cellular components or other contaminants, such as other cellular nucleic acids or proteins, by standard techniques, including column chromatography and other techniques well known in the art (see Ausubel, F. et al., eds., Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987)). Expression in NSO cells is described, for example, by Barnes, LM et al., Cytotechnology 32 (2000) 109-123; Barnes, LM et al., Biotech. Bioeng. 73 (2001) 261-270. Transient expression is described, for example, by Durocher, Y. et al., Nucl. Acids. Res. 30 (2002) E9. Cloning of variable domains is described by Orlandi, R. et al., Proc. Natl. Acad. Sci. USA 86 (1989) 3833-3837; Carter, P. et al., Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289; Norderhaug, L. et al., J. Immunol. Methods 204 (1997) 77-87.Preferred transient expression systems (HEK 293) are described by Schlaeger, E.-J. and Christensen, K., in Cytotechnology 30 (1999) 71-83 and by Schlaeger, E.-J., in J. Immunol. Methods 194 (1996) 191-199. Monoclonal antibodies are suitably isolated from the culture medium by conventional immunoglobulin purification procedures, such as protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. DNA and RNA encoding monoclonal antibodies can be readily isolated and sequenced using conventional procedures. Hybridoma cells can serve as a source of such DNA and RNA. Once isolated, the DNA can be inserted into an expression vector and subsequently transfected into a host cell that does not otherwise produce immunoglobulin protein, such as HEK 293 cells, CHO cells, or myeloma cells, to obtain synthesis of recombinant monoclonal antibodies in the host cell.
[0114] The heavy chain and light chain variable domains according to the present invention are combined with a promoter sequence, a translation initiation sequence, a constant region sequence, a 3' untranslated region sequence, a polyadenylation sequence, and a transcription termination sequence to form an expression vector construct. The heavy chain and light chain expression constructs can be combined into a single vector, co-transfected, serially transfected, or separately transfected into a host cell, which is then fused to form a single host cell expressing both the heavy chain and the light chain.
[0115] It is understood that the antibody is administered to the subject in a therapeutically effective amount, which is an amount of a compound or combination of the invention that elicits the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, physician or other clinician. Recombinant fusion protein-Neuregulin
[0116] In one embodiment, the recombinant fusion protein provided by the present invention comprises a fragment of NRG-1 protein. NRG protein can bind to the ErbB4 receptor on the surface of cardiomyocytes, continuously activate the PI3K / AKT signaling pathway in the cells, and change the structure of cardiomyocytes, thereby improving the function of cardiomyocytes.
[0117] As used in the present invention, "neuregulin" or "NRG" refers to a protein or peptide that can bind to and activate ErbB3, ErbB4 or their heterodimers or homodimers, including neuregulin isoforms, neuregulin EGF-like domains, polypeptides containing neuregulin EGF-like domains, neuregulin mutants or derivatives, and any type of neuregulin-like gene products that can activate the above receptors. Neuregulin also includes NRG-1, NRG-2, NRG-3 and NRG-4 proteins, peptides, fragments and compounds that have neuregulin functions. In a preferred embodiment, the neuregulin is a protein or peptide that can bind to and activate ErbB2 / ErbB4 or ErbB2 / ErbB3 heterodimers, for example but not for the purpose of limitation, the peptides of the present invention include fragments of NRG-1β2 isoforms, i.e., 177-237 amino acid fragments, which contain an EGF-like domain having the following amino acid sequence: SHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCQNYVMASFYKAEELYQ (SEQ ID NO: 4). The NRG proteins of the present invention can activate the above receptors and regulate their biological functions, such as stimulating the synthesis of acetylcholine receptors in skeletal muscle cells, promoting differentiation and survival of cardiomyocytes, and DNA synthesis. It is well known to those skilled in the art that mutations of single amino acids in non-critical regions generally do not change the biological activity of the resulting protein or polypeptide (see, for example, Watson et al., Molecular Biology of the Gene, 4th edition, 1987, The Bejacmin / Cummings Pub.co., page 224). The NRG protein of the present invention can be isolated from natural sources, and can be modified through recombinant technology, artificial synthesis or other means.
[0118] As used herein, "epidermal growth factor-like domain" or "EGF-like domain" refers to a polypeptide fragment encoded by the neuregulin gene, which fragment binds to and activates ErbB3, ErbB4, or heterodimers or homodimers thereof and includes heterodimers with ErbB2, and is structurally similar to the EGF receptor binding region, such as WO 00 / 64400, Holmes et al., Science, 256:1205-1210 (1992); U.S. Pat. Nos. 5,530,109 and 5,716,930; Hijazi et al., Int. J. Oncol., 13:1061-1067 (1998); Chang et al., Nature, 387:509-512 (1997); Carraway et al., Nature, 387:512-516 (1997); Higashiyama et al., J. Biochem., 122:675-680 (1997); and WO97 / 09425, the contents of which are incorporated herein by reference in their entirety. In certain embodiments, the EGF-like domain binds to and activates ErbB2 / ErbB4 or ErbB2 / ErbB3 heterodimers. In certain embodiments, the EGF-like domain comprises the amino acid sequence of the receptor binding domain of NRG-1. In some embodiments, the EGF-like domain refers to amino acid residues 177-226, 177-237, or 177-240 of NRG-1. In certain embodiments, the EGF-like domain comprises the amino acid sequence of the receptor binding domain of neuregulin-2 (NRG-2, also known in the art as DON1, HRG2, and NTAK). In certain embodiments, the EGF-like domain of NRG-2 comprises the sequence of HARKCNETAKSYCVNGGVCYYIEGINQLSCKCPNGFFGQRCL (SEQ ID NO: 15). In certain embodiments, the EGF-like domain comprises the amino acid sequence of the receptor binding domain of neuregulin 3 (NRG-3, also known in the art as HRG3 and pro-NRG3). In certain embodiments, the EGF-like domain of NRG-3 comprises the sequence of HFKPCRDKDLAYCLNDGECFVIETLTGSHKHCRCKEGYQGVRCD (SEQ ID NO: 16). In certain embodiments, the EGF-like domain comprises the amino acid sequence of the receptor binding domain of neuregulin 4 (NRG-4, also known in the art as HER4). In certain embodiments, the EGF-like domain of NRG-4 comprises the sequence of HEEPCGPSHKSFCLNGGLCYVIPTIPSPFCRCVENYTGARCE (SEQ ID NO: 17).In certain embodiments, the EGF-like domain comprises the amino acid sequence of Ala Glu Lys Glu Lys ThrPhe Cys Val Asn Gly Glu Cys Phe Met Val Lys Asp Leu Ser Asn Pro (SEQ ID NO: 18) as described in U.S. Pat. No. 5,834,229.
[0119] In one embodiment, the NRG-1 protein provided in the recombinant fusion protein disclosed in the present invention is an NRG-1β2a isoform.
[0120] In some embodiments, the active NRG-1 fragment comprises an ERBB3 / 4 binding domain. In another related embodiment, NRG-1 binds to ErbB4 (HER4) and induces signaling therethrough. In other embodiments, the mAb inhibits NRG-1 signaling through ErbB3 (HER3). In some embodiments, the active protein fragment of NRG-1 comprises an active domain of NRG-1.
[0121] In some embodiments, the NRG-1 fragment comprises SEQ ID NO: 4, or a sequence at least 70%, at least 80%, at least 90%, or at least 95% identical thereto, and is capable of binding to ErbB4 and inducing signaling therethrough. Recombinant fusion protein-composition
[0122] In one embodiment, in the recombinant fusion protein disclosed in the present invention, NRG-1 is fused to the C-terminus of the heavy chain of the anti-HER3 antibody using a linker. In another related aspect, NRG-1 is fused to the C-terminus of the heavy chain of the anti-HER3 antibody via the first (1 st) amino acid is connected to the linker, which amino acid is a serine (S or Ser) amino acid in one embodiment. The specific recombinant fusion protein used in the present invention can be optionally obtained or formed by any method known in the art (including purchase from commercial sources). For example, a nucleic acid sequence encoding an appropriate antibody framework is optionally cloned and connected to an appropriate vector (e.g., an expression vector for, for example, a prokaryotic or eukaryotic organism). In addition, a nucleic acid sequence encoding an NRG-1β2a isoform molecule is optionally cloned into the same vector in an appropriate direction and position so as to produce an antibody-NRG-1β2a isoform fusion protein by self-expression of the vector. Some optional embodiments also require post-expression modifications, such as assembly of antibody subunits, etc. The techniques and processes for the above (and similar) operations are well known to those skilled in the art. Related descriptions can be found in, for example, Sambrook et al., Molecular Cloning-A Laboratory Manual (2nd Edition), Volumes 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989 and Current Protocols in Molecular Biology, FM Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (supplemented to 1999). In some alternative embodiments, the antibody domain and NRG-1β2a isoform are assembled after expression, for example, by chemical means. In one embodiment, the present invention provides a composition, for example, a pharmaceutical composition comprising a recombinant fusion protein of the present invention.
[0123] In one embodiment, the recombinant fusion protein reduces the duration of atrial fibrillation episodes. In one embodiment, the recombinant fusion protein reduces the frequency of atrial fibrillation. Symptoms of atrial fibrillation include, but are not limited to, irregular heartbeat, palpitations, dizziness, extreme fatigue, shortness of breath, chest pain, and combinations thereof. In one embodiment, the recombinant fusion protein reduces collagen content or deposition in cardiac tissue.
[0124] In one embodiment, the recombinant fusion protein promotes cardiomyocyte proliferation, differentiation and survival. In another embodiment, the recombinant fusion protein promotes the proliferation, differentiation and survival of cardiac tissue. In one embodiment, the recombinant fusion protein promotes the proliferation, differentiation and survival of cardiomyocytes without promoting cancer and / or tumor growth. In another embodiment, the recombinant fusion protein promotes the proliferation, differentiation and survival of cardiac tissue without promoting cancer or tumor growth.
[0125] In one embodiment, the cancer is adrenocortical carcinoma, AIDS-related cancer, AIDS-related lymphoma, anal cancer, anorectal cancer, anal canal cancer, appendix cancer, childhood cerebellar astrocytoma, childhood brain astrocytoma, basal cell carcinoma, skin cancer (non-melanoma), biliary tract cancer, extrahepatic bile duct cancer, intrahepatic bile duct cancer, bladder cancer, bladder cancer, bone and joint cancer, osteosarcoma and malignant fibrous histiocytoma, brain cancer, brain tumor, brain stem glioma, cerebellar astrocytoma, brain astrocytoma / malignant glioma, ventricular Tubuloma, medulloblastoma, supratentorial primitive neuroectodermal tumor, optic pathway and hypothalamic glioma, breast cancer, bronchial adenoma / carcinoid, carcinoid tumor, gastrointestinal cancer, nervous system cancer, nervous system lymphoma, central nervous system cancer, central nervous system lymphoma, cervical cancer, childhood cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disease, colon cancer, colorectal cancer, cutaneous T-cell lymphoma, lymphoid neoplasm, mycosis fungoides, Sezary syndrome Syndrome), endometrial cancer, esophageal cancer, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor, glioma, head and neck cancer, hepatocellular (liver) cancer, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, eye cancer, islet cell tumor (endocrine pancreas), Kaposi sarcoma Sarcoma), kidney cancer, renal cancer, renal cancer, laryngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, lip and oral cancer, liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, AIDS-related lymphoma, non-Hodgkin lymphoma, primary central nervous system lymphoma, Waldenstroemmacroglobulinemia, medulloblastoma, melanoma, intraocular (eye) melanoma, merkel cell carcinomacarcinoma), malignant mesothelioma, mesothelioma, metastatic squamous neck cancer, oral cancer, tongue cancer, multiple endocrine neoplasia syndrome, mycosis fungoides, myelodysplastic syndrome, myelodysplastic / myeloproliferative disease, chronic myeloid leukemia, acute myeloid leukemia, multiple myeloma, chronic myeloproliferative disease, nasopharyngeal cancer, neuroblastoma, oral cancer, oral cancer, oropharyngeal cancer, ovarian cancer, ovarian epithelial cancer, ovarian low-grade malignant potential tumor, pancreatic cancer, islet cell pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineoblastoma and supratentorial primitive neuroectodermal tumor, pituitary tumor, plasma cell tumor / multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal pelvis and ureter cancer, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Ewing family of sarcoma tumors tumor), Kaposi's sarcoma, soft tissue sarcoma, epithelioid sarcoma, synovial sarcoma, uterine cancer, uterine sarcoma, skin cancer (non-melanoma), skin cancer (melanoma), Merkel cell skin cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, supratentorial primitive neuroectodermal tumor, testicular cancer, pharyngeal cancer, thymoma, thymoma and thymic carcinoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter and other urinary organs, gestational trophoblastic tumor, urethral cancer, endometrial uterine cancer, uterine sarcoma, uterine corpus cancer, vaginal cancer, vulvar cancer, or Wilm's Tumor.
[0126] In another embodiment, the recombinant fusion protein promotes the proliferation, differentiation and survival of central nervous system (CNS) cells. In another embodiment, the recombinant fusion protein promotes the proliferation, differentiation and survival of central nervous system (CNS) cells without promoting cancer and / or tumor growth. In another embodiment, the recombinant fusion protein has a reduced ability to induce antibody-dependent cellular cytotoxicity (ADCC).
[0127] In some embodiments, the recombinant fusion protein promotes HER2 / 4 signaling over HER2 / 3 signaling relative to the signal induction potential of recombinant NRG-1.
[0128] In another specific embodiment of the invention, the recombinant fusion protein comprises an anti-HER3 mAb fused to the NRG-1β2a isoform of SEQ ID NO: 4 or operably linked to the C-terminus of the antibody heavy chain via a GGGGSGGGGS (G4S) linker (SEQ ID NO: 5). In some embodiments, one or more copies of the linker may be used. In other embodiments, 2, 3, 4, or 5 copies of the G4S linker or any other linker known in the art to be suitable for use in the compositions disclosed herein may be used in the present invention.
[0129] The term "linker" is recognized in the art and refers to a molecule (including but not limited to unmodified or modified nucleic acids or amino acids) or a group of molecules (e.g., 2 or more, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more) that connects two compounds, such as two polypeptides. A linker may consist of a single linker molecule, or may comprise a linker molecule and at least one spacer molecule, which is intended to separate the linker molecule and the compound by a specific distance.
[0130] A nucleic acid is "operably linked" when it is in a functional region with another nucleic acid sequence. For example, if a nucleic acid presequence or secretory leader sequence is expressed as a preprotein that participates in the secretion of a polypeptide, it is operably linked to a nucleic acid encoding the polypeptide; if a promoter or enhancer affects the transcription of a coding sequence, it is operably linked to the sequence; or if a ribosome binding site is positioned so as to facilitate translation, it is operably linked to a coding sequence. In general, "operably linked" means that the linked nucleic acid sequences are adjacent, and in the case of a secretory leader sequence, adjacent and in the reading frame. However, enhancers are optionally adjacent. Connection can be achieved, for example, by joining at appropriate restriction sites. If such sites do not exist, synthetic oligonucleotide adapters, linkers, or other methods known in the art can be used. In another embodiment, "operably linked" also refers to the functional pairing of different amino acid sequences, peptides or proteins, such as the antibodies and NRG-1 fragments described in the present invention are paired via linker sequences also described in the present invention.
[0131] In another embodiment, the anti-HER3 mAb heavy chain contained in the recombinant fusion protein provided by the present invention is encoded by SEQ ID NO: 6:
[0132] In one embodiment, the recombinant fusion protein provided by the present invention comprises the heavy chain of anti-HER3 mAb. In another embodiment, the heavy chain of anti-HER3 mAb is encoded by SEQ ID NO:7:
[0133] In one embodiment, the recombinant fusion protein provided by the present invention comprises the light chain sequence of anti-HER3 mAb. In another embodiment, the light chain sequence is encoded by (SEQ ID NO: 8): (SEQ ID NO:8). In one embodiment, SEQ ID NO:8 is also referred to as "PAL".
[0134] In one embodiment, the heavy chain of the anti-HER3 antibody contained in the recombinant fusion protein provided by the present invention comprises the following amino acid sequence: (SEQ ID NO:9).
[0135] In one embodiment, the heavy chain of the anti-HER3 antibody contained in the recombinant fusion protein provided by the present invention comprises the following amino acid sequence: (SEQ ID NO: 10).
[0136] In one embodiment, the anti-HER3 mAb heavy chain sequence comprises a signal peptide sequence. In another embodiment, the anti-HER3 mAb heavy chain signal peptide sequence comprises an amino acid sequence of MEFGLSWVFLVAIIKGVQC (SEQ ID NO: 11).
[0137] In one embodiment, the light chain of the anti-HER3 antibody comprised by the recombinant fusion protein comprises the following amino acid sequence: MVLQTQVFISLLLWISGAYGDIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 12).
[0138] In one embodiment, the anti-HER3 mAb light chain sequence comprises a signal peptide sequence. In another embodiment, the anti-HER3 mAb light chain signal peptide sequence comprises an amino acid sequence of MVLQTQVFISLLLWISGAYG (SEQ ID NO: 13). In one embodiment, the mature polypeptide disclosed in the present invention, such as an antibody heavy chain or light chain amino acid sequence, lacks a signal peptide.
[0139] In one embodiment, the recombinant fusion protein comprises the following amino acid sequence: Heavy chain (SEQ ID NO: 14, wherein bold italics indicate a linker, and bold indicates an NRG-1 fragment); and Light chain DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:3).
[0140] In one embodiment, both the heavy chain sequence and the light chain sequence in the mature recombinant fusion protein lack a signal peptide amino acid sequence.
[0141] In another specific embodiment of the present invention, the heavy chain of the anti-HER3 antibody provided by the present invention is fused to the NRG-1β2a isoform provided by the present invention via a C-terminal linker sequence. In another embodiment, the C-terminus of the antibody heavy chain comprises the Fc domain of the antibody.
[0142] In some embodiments, a pharmaceutical composition is provided, which comprises a recombinant fusion protein disclosed herein formulated together with a pharmaceutical carrier.
[0143] In some embodiments, the anti-HER3 antibody and NRG-1 fragment described in the present invention are fused / operably linked via a linker in a recombinant or chemical manner to form a fusion protein. "Fusion protein", "fusion polypeptide", "recombinant fusion protein" or "recombinant polypeptide" refers to a mixed polypeptide comprising polypeptide portions from at least two different polypeptides. As defined in the present invention, a "fusion protein" is a fusion comprising, for example, a first amino acid sequence (protein) of an NRG-1β2a isoform of the present invention joined to the C-terminus of a second amino acid sequence of an antibody heavy chain that specifically binds to ERBB3 (HER3) via a linker.
[0144] In one embodiment, the fusion protein is encoded and produced in a recombinant manner. In some embodiments, the recombinant fusion protein is encoded by a nucleic acid sequence encoding an antibody of the invention, which is operably linked to a nucleic acid sequence encoding an NRG-1β2a isoform of the invention via a nucleic acid sequence encoding a linker.
[0145] In one embodiment, the recombinant fusion protein amino acid sequence is homologous to SEQ ID NO: 14 fused to SEQ ID NO: 3. The term "homology" may refer to an identity greater than 70% with a recombinant fusion protein sequence (e.g., any one of SEQ ID NOs: 1-18). In another embodiment, "homology" refers to an identity greater than 72% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 75% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 78% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 80% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 82% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 83% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 85% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 87% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 88% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 90% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 92% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 93% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 95% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 96% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 97% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 98% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 99% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity of 100% with any one of SEQ ID NOs: 1-18.
[0146] The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, as modified in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877. Such algorithms are incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program (score = 100, wordlength = 12) to obtain nucleotide sequences homologous to nucleic acids encoding a protein of interest. BLAST protein searches can be performed with the XBLAST program (score = 50, wordlength = 3) to obtain amino acid sequences homologous to a protein of interest. In order to obtain gap alignments for comparison purposes, gap BLAST can be used as described in Altschul et al., 1997, Nucleic Acids Res. 25: 3389-3402. Alternatively, PSI-Blast can be used for iterative searches to detect distance relationships (id.) between molecules. When using BLAST, gap BLAST, and PSI-BLAST programs, the default parameters of each program (e.g., XBLAST and NBLAST) can be used. Another non-limiting example of a mathematical algorithm for sequence comparison is the algorithm of Myers and Miller, CABIOS (1989). Such algorithms are incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When the ALIGN program is used to compare amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Other algorithms for sequence analysis are known in the art and include ADVANCE and ADAM as described in Torellis and Robotti, 1994, Comput. Appl. Biosci. 10:3-5; and FASTA as described in Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85:2444-8. In FASTA, ktup is a control option that sets the sensitivity and speed of the search. If ktup=2, similar regions in the two sequences being compared are found by observing pairs of aligned residues; if ktup=1, single aligned amino acids are examined. ktup can be set to 2 or 1 for protein sequences, or to 1 to 6 for DNA sequences. If ktup is not specified, the default value is 2 for proteins and 6 for DNA.Alternatively, protein sequence alignments can be performed using the CLUSTAL W algorithm as described by Higgins et al., 1996, Methods Enzymol. 266:383-402.
[0147] In some embodiments, the polynucleotides of the present invention are prepared using PCR technology, using procedures and methods known to those skilled in the art. In some embodiments, the procedure involves the joining of two different DNA sequences (see, for example, "Current Protocols in Molecular Biology", Ausubel et al., ed., John Wiley & Sons, 1992).
[0148] In one embodiment, the polynucleotide of the present invention is inserted into an expression vector (i.e., a nucleic acid construct) to facilitate the expression of a recombinant polypeptide. In one embodiment, the expression vector of the present invention includes additional sequences that make this vector suitable for replication and integration in prokaryotes. In one embodiment, the expression vector of the present invention includes additional sequences that make this vector suitable for replication and integration in eukaryotes. In one embodiment, the expression vector of the present invention includes a shuttle vector that makes this vector suitable for replication and integration in prokaryotes and eukaryotes. In some embodiments, the cloning vector comprises transcription and translation initiation sequences (e.g., promoters, enhancers) and transcription and translation terminators (e.g., polyadenylation signals).
[0149] In one embodiment, a variety of prokaryotic or eukaryotic cells can be used as host expression systems to express the polypeptides of the present invention. In some embodiments, these include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing polypeptide coding sequences; yeast transformed with recombinant yeast expression vectors containing polypeptide coding sequences.
[0150] In some embodiments, a non-bacterial expression system (e.g., a mammalian expression system, such as CHO cells) is used to express the polypeptides of the invention. In one embodiment, the expression vector used to express the polynucleotides of the invention in mammalian cells is a pCI-DHFR vector comprising a CMV promoter and a neomycin resistance gene.
[0151] In some embodiments, in the bacterial system of the present invention, a variety of expression vectors can be advantageously selected according to the intended use of the expressed polypeptide. In one embodiment, a large amount of polypeptide is required. In one embodiment, a carrier is required to guide the expression of a high level of protein product, which may be expressed as a fusion with a hydrophobic signal sequence, which guides the expressed product to the bacterial periplasm or culture medium, where the protein product is easily purified. In one embodiment, some fusion proteins are engineered to have specific cleavage sites to help recover the polypeptide. In one embodiment, carriers that can be adapted to such operations include, but are not limited to, the E. coli expression vectors of the pET series [Studier et al., Methods in Enzymol. 185: 60-89 (1990)].
[0152] In one embodiment, a yeast expression system is used. In one embodiment, a number of vectors containing constitutive or inducible promoters can be used in yeast, as disclosed in U.S. Pat. No. 5,932,447. In another embodiment, a vector that promotes integration of foreign DNA sequences into yeast chromosomes is used.
[0153] In one embodiment, the expression vector of the present invention may further include additional polynucleotide sequences allowing, for example, translation of several proteins from a single mRNA, such as an internal ribosome entry site (IRES) and sequences for genomic integration of the promoter chimeric polypeptide.
[0154] In some embodiments, the expression vector of the present invention includes elements that increase the expression of the recombinant fusion protein of the present invention. Such features include, but are not limited to, the selection of promoters and polyadenylation. In some embodiments, the polyadenylation sequence is a bovine growth hormone (BGH) polyadenylation sequence. In some embodiments, the promoter includes a constitutively active promoter. In some embodiments, the promoter includes a cytomegalovirus promoter (pCMV).
[0155] In some embodiments, mammalian expression vectors include, but are not limited to, pcDNA3, pcDNA3.1(+ / -), pGL3, pZeoSV2(+ / -), pSecTag2, pDisplay, pEF / myc / cyto, pCMV / myc / cyto, pCR3.1, pSinRep5, DH26S, DHBB, pNMT1, pNMT41, pNMT81, which can be purchased from Invitrogen; pCI, which can be purchased from Promega; pMbac, pPbac, pBK-RSV and pBK-CMV, which can be purchased from Strategene; pTRES, which can be purchased from Clontech; and derivatives thereof.
[0156] In some embodiments, the present invention uses expression vectors containing regulatory elements from eukaryotic viruses such as retroviruses. SV40 vectors include pSVT7 and pMT2. In some embodiments, vectors derived from bovine papilloma virus include pBV-1MTHA, and vectors derived from Epstein Barr virus include pHEBO and p205. Other exemplary vectors include pMSG, pAV009 / A + \pMTO10 / A + , pMAMneo-5, baculovirus pDSVE, and any other vector that allows expression of a protein under the direction of the SV-40 early promoter, the SV-40 late promoter, the metallothionein promoter, the mouse mammary tumor virus promoter, the Rous sarcoma virus promoter, the polyhedrin promoter, or other promoters shown to be effective for expression in eukaryotic cells.
[0157] In some embodiments, recombinant viral vectors can be used for in vivo expression of polypeptides of the present invention because they provide advantages such as lateral infection and targeting specificity. In one embodiment, lateral infection is inherent in the life cycle of, for example, retroviruses, and is the process by which a single infected cell produces many progeny virions that bud and infect adjacent cells. In one embodiment, the result is that large areas are rapidly infected, most of which were not initially infected by the original virions. In one embodiment, a viral vector that cannot spread laterally is produced. In one embodiment, this feature may be useful if the intended purpose is to introduce a specific gene only into a local number of target cells.
[0158] In one embodiment, various methods can be used to introduce expression vectors encoding recombinant fusion proteins of the present invention into cells. Such methods are generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992); Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989); Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995); Vega et al., Gene Targeting, CRC Press, Ann Arbor Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston Mass. (1988) and Gilboa et al. [Biotechniques 4 (6): 504-512, 1986], and include, for example, stable or transient transfection, lipofection, electroporation, and infection with recombinant viral vectors. In addition, regarding the positive-negative selection method, see US Pat. Nos. 5,464,764 and 5,487,992.
[0159] In some embodiments, introduction of nucleic acids by viral infection offers several advantages over other methods, such as lipofection and electroporation, because higher transfection efficiencies can be obtained due to the infectious nature of the virus.
[0160] In one embodiment, it should be understood that the polypeptides of the present invention can also be expressed by nucleic acid constructs administered to individuals using any suitable mode of administration described above (i.e., in vivo gene therapy). In one embodiment, the nucleic acid construct is introduced into suitable cells via appropriate gene delivery vectors / methods (transfection, transduction, homologous recombination, etc.) and expression systems (optionally), and the modified cells are subsequently amplified in culture and returned to the individual (i.e., in vitro gene therapy).
[0161] It will be appreciated that, in addition to containing the necessary elements for the transcription and translation of the inserted coding sequence (encoding a polypeptide), the expression constructs of the invention may also include sequences engineered to optimize the stability, production, purification, yield or activity of the expressed polypeptide.
[0162] In some embodiments, the transformed cells are cultured under effective conditions that allow expression of a large amount of recombinant fusion proteins or polypeptides. In some embodiments, effective culture conditions include but are not limited to effective culture medium, bioreactor, temperature, pH and oxygen conditions that allow protein production. In one embodiment, effective culture medium refers to any culture medium in which cells are cultured to produce recombinant polypeptides of the present invention. In some embodiments, culture medium generally includes an aqueous solution with absorbable carbon, nitrogen and phosphate sources and appropriate salts, minerals, metals and other nutrients such as vitamins. In some embodiments, cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter plates and culture dishes. In some embodiments, culture is carried out at a temperature, pH and oxygen content suitable for recombinant cells. In some embodiments, culture conditions are within the professional knowledge of those of ordinary skill in the art.
[0163] In some embodiments, depending on the vector and host system used for production, the resulting polypeptide of the present invention is retained within the recombinant cell, secreted into the fermentation medium, secreted into the space between two cell membranes (such as the periplasmic space of E. coli); or retained on the outer surface of the cell or viral membrane.
[0164] In one embodiment, after a predetermined incubation time, recovery of the recombinant polypeptide is achieved.
[0165] In one embodiment, the phrase "recovering the recombinant polypeptide" as used herein refers to collecting the entire fermentation medium containing the polypeptide, without implying additional separation or purification steps.
[0166] In one embodiment, the polypeptides of the invention are purified using a variety of standard protein purification techniques such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing, and differential solubility.
[0167] In one embodiment, to facilitate recovery, the expressed coding sequence may be engineered to encode a polypeptide of the invention and a fused cleavable moiety. In one embodiment, the fusion protein may be designed so that the polypeptide can be easily separated by affinity chromatography; for example, by being immobilized on a column specific for the cleavable moiety. In one embodiment, the cleavage site is engineered between the polypeptide and the cleavable moiety, and the polypeptide can be released from the chromatography column by treatment with an appropriate enzyme or agent that specifically cleaves the fusion protein at this site [see, for example, Booth et al., Immunol. Lett. 19: 65-70 (1988); and Gardella et al., J. Biol. Chem. 265: 15854-15859 (1990)].
[0168] In one embodiment, a polypeptide of the invention is recovered in a "substantially pure" form.
[0169] In one embodiment, the phrase "substantially pure" refers to a degree of purity that allows the protein to be effectively used in the applications described herein.
[0170] In one embodiment, the polypeptides of the present invention can also be synthesized using an in vitro expression system. In one embodiment, in vitro synthesis methods are well known in the art, and the components of the system are commercially available.
[0171] In some embodiments, recombinant polypeptides are synthesized and purified; their therapeutic efficacy can be analyzed in vivo or in vitro.
[0172] In one embodiment, the pharmaceutical composition provided by the present invention comprising the recombinant fusion protein of the present invention is further formulated with a pharmaceutical carrier. As used herein, "pharmaceutical carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delay agents and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Treatment
[0173] In one embodiment, the present invention provides a method of treating a disease or condition in a subject in need thereof, the method comprising administering a therapeutically effective amount of a recombinant fusion protein or a pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
[0174] In one embodiment, the present invention provides a method of treating a cardiovascular disease or condition in a subject in need thereof, the method comprising administering a therapeutically effective amount of a recombinant fusion protein or a pharmaceutical composition comprising the same.
[0175] In one embodiment, the present invention provides a method for preventing, inhibiting, suppressing or delaying the onset of a cardiovascular disease or condition in a subject, the method comprising administering an effective amount of the recombinant fusion protein or pharmaceutical composition of the present invention.
[0176] In some embodiments, the cardiovascular disease or condition comprises atrial fibrillation.
[0177] In some embodiments, the cardiovascular disease or condition comprises cardiac fibrosis.
[0178] In some embodiments, cardiovascular diseases or conditions include atrial fibrillation and cardiac fibrosis.
[0179] In some embodiments, cardiovascular diseases include chronic heart failure / congestive heart failure (CHF), acute heart failure / myocardial infarction (MI), left ventricular systolic dysfunction, reperfusion injury associated with MI, chemotherapy-induced cardiotoxicity (adults or children), radiation-induced cardiotoxicity, adjunctive treatment with surgical intervention for congenital heart disease in children.
[0180] In some embodiments, wherein chemotherapy-induced cardiotoxicity results from a subject receiving anthracyclines, alkylating agents, anti-microtubule agents, and antimetabolite agents as chemotherapy.
[0181] In some embodiments, the cardiovascular condition is cardiotoxicity caused by the subject receiving cancer therapy. In other embodiments, the cancer therapy is a HER-2 targeted therapy. In other embodiments, the HER-2 targeted therapy comprises the use of trastuzumab, adotrastuzumab, emtansine, lapatinib, neratinib and pertuzumab, any anti-HER2 antibody, any anti-HER2 agent, or a combination thereof.
[0182] In another aspect, the present invention relates to a method for inducing sarcomere and cytoskeleton structure remodeling or cell-cell adhesion in muscle cells, which comprises treating cells with the recombinant fusion protein disclosed in the present invention.
[0183] In one embodiment, the method of treatment is directed to treating heart failure caused by dissociation of cardiomyocyte-cell adhesions and / or sarcomere structural disturbances in a mammal.
[0184] In another aspect, the present invention provides a method for preventing, treating or delaying heart failure with preserved ejection fraction in humans, the method comprising administering a pharmaceutical composition comprising the recombinant fusion protein disclosed in the present invention.
[0185] As used herein, the term "ejection fraction" refers to the ejection fraction (EF), which is a measurement of how much blood the left ventricle pumps out each time it contracts, usually expressed as a percentage. For example, an ejection fraction of 50% means that 50% of the total amount of blood in the left ventricle is ejected in each heartbeat.
[0186] The present invention relates to treating subjects suffering from or at risk for heart disease and related conditions such as heart failure.
[0187] The term "heart failure" refers to abnormal cardiac function in which the heart cannot pump blood at the rate required by metabolic tissues. Heart failure includes various disease states, such as congestive heart failure, myocardial infarction, tachycardia, familial hypertrophic cardiomyopathy, ischemic heart disease, idiopathic dilated cardiomyopathy, and myocarditis. Heart failure can be caused by a variety of factors, including ischemic, congenital, rheumatic, or idiopathic forms. Chronic cardiac hypertrophy is a serious disease state that is a precursor to congestive heart failure and cardiac arrest.
[0188] In one embodiment, "treatment" refers to therapeutic treatment and preventive or prophylactic measures, the purpose of which is to prevent or slow down (reduce) cardiac hypertrophy. Those in need of treatment include those who already have the disease and those who are susceptible to the disease or need to prevent the disease. Cardiac hypertrophy can come from any cause that responds to retinoic acid, including congenital, viral, idiopathic, cardiotrophic or myotrophic causes, or due to ischemia or ischemic injury, such as myocardial infarction. Typically, treatment is performed to prevent or slow the progression of hypertrophy, especially after cardiac damage such as from ischemia has occurred. Preferably, for the treatment of myocardial infarction, the pharmaceutical composition provided by the present invention is administered immediately after the myocardial infarction to prevent or reduce hypertrophy.
[0189] In some embodiments, treating a subject with atrial fibrillation or cardiac fibrosis with the recombinant fusion protein of the present invention or a pharmaceutical composition comprising the same can result in reducing the signs or symptoms of atrial fibrillation or fibrosis. For example, treating a subject with the recombinant fusion protein can reduce the duration and / or frequency of atrial fibrillation, or reduce the signs or symptoms of atrial fibrillation, such as reducing irregular heartbeat, palpitations, dizziness, extreme fatigue, shortness of breath, chest pain, or a combination thereof. In some embodiments, treating a subject with the recombinant fusion protein reduces the content or deposition of collagen in cardiac tissue, such as atrial tissue.
[0190] In some embodiments, compared to a group receiving a monotherapy of a drug that is not a compound of the present invention or a pharmaceutically acceptable salt, solvate, analog or derivative thereof, treating a subject with a pharmaceutical composition comprising a recombinant fusion protein provided by the present invention can increase the average survival time of the treated subject group. Preferably, after treatment with the strategies, treatment methods, methods, combinations and compositions provided by the present invention, the average survival time increases by more than 30 days; more preferably more than 60 days; more preferably more than 90, 120 or 365 days; more preferably more than 365 days. The increase in the average survival time of the group can be measured by any reproducible means. The increase in the average survival time of the group can be measured, for example, by calculating the average survival time length of the group after starting treatment with an active compound. The increase in the average survival time of the group can also be measured, for example, by calculating the average survival time length of the group after completing the first round of treatment of the pharmaceutical composition disclosed in the present invention.
[0191] In some embodiments, treating a subject with a pharmaceutical composition comprising a recombinant fusion protein provided by the present invention can reduce the mortality rate of the treated subject population compared to the population receiving only the carrier. Treating cancer can reduce the mortality rate of the treated subject population compared to the untreated population. Compared with a population receiving a monotherapy of a drug or a pharmaceutically acceptable salt, solvate, analog or derivative of a non-compound of the present invention, treating cancer can result in a reduced mortality rate in the treated subject population. Preferably, after treatment with the strategies, treatment methods, methods, combinations and compositions provided by the present invention, the mortality rate is reduced by more than 2%; more preferably more than 5%; more preferably more than 10%; and most preferably more than 25%. The reduction in the mortality rate of the treated subject population can be measured by any reproducible means. The reduction in the mortality rate of the population can be measured, for example, by calculating the average number of deaths related to the disease per unit time after the population begins treatment with the active compound. The reduction in the mortality rate of the population can also be measured, for example, by calculating the average number of deaths related to the disease per unit time after the first round of treatment of the pharmaceutical composition disclosed by the present invention.
[0192] In one embodiment, the present invention provides a method for treating a central nervous system (CNS)-related disease or condition in a subject in need thereof, the method comprising administering a therapeutically effective amount of the recombinant fusion protein or pharmaceutical composition of the present invention.
[0193] In one embodiment, the present invention provides a method for preventing, inhibiting, suppressing or delaying the onset of a CNS-related disease or condition in an individual, the method comprising administering an effective amount of the recombinant fusion protein or pharmaceutical composition of the present invention.
[0194] In some embodiments, the CNS-related disease or condition is amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Bell's palsy, epilepsy and seizures, Guillain-Barre syndrome, stroke, traumatic brain injury, multiple sclerosis, or a combination. Administration, dosage
[0195] The composition of the present invention can be administered to a subject in need parenterally, or can be administered by various methods known in the art. As will be appreciated by those skilled in the art, the route of administration and / or mode will vary depending on the desired result. In order to administer the compounds of the present invention by certain routes of administration, it may be necessary to coat the compound with a material or co-administer the compound with a material to prevent its inactivation. For example, the compound can be administered to a subject in an appropriate carrier (e.g., liposomes or diluents). Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Pharmaceutical carriers include sterile aqueous solutions or dispersions and sterile powders for the temporary preparation of sterile injectable solutions or dispersions. The use of such media and medicaments for pharmaceutically active substances is known in the art.
[0196] In typical embodiments, the preparations administered to the subject include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Some embodiments include non-aqueous solvents, such as propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), organic esters (e.g., ethyl oleate) and other solvents known to those skilled in the art. Physiologically acceptable carriers (or excipients) are optionally used in certain embodiments of the present invention. Such examples include, for example, normal saline, PBS, Ringer's solution, lactated Ringer's solution, etc. In addition, preservatives and additives are optionally added to the composition to help ensure stability and sterility. For example, antibiotics and other bactericides, antioxidants, chelating agents and the like are optionally present in various embodiments of the present composition.
[0197] As used herein, the phrases "parenteral administration" and "parenteral administration" refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.
[0198] Regardless of the administration route selected, the compound of the present invention and / or the pharmaceutical composition of the present invention, which can be used in a suitable hydrated form, is formulated into a pharmaceutically acceptable dosage form by conventional methods known to those skilled in the art.
[0199] The recombinant fusion protein or a pharmaceutical composition comprising it is optionally administered to a subject in need of treatment (therapeutic or preventive) in any suitable sterile pharmaceutical carrier. Such pharmaceutical carriers are used to maintain the solubility and effect of the fusion protein. In some embodiments, additional components may need to be administered in conjunction with the fusion protein. For example, in some treatment regimens, chemotherapeutic agents, antibiotics, additional formulations comprising the recombinant fusion protein of the present invention, and one or more standard of care agents, etc. are all optionally included in the composition of the present invention.
[0200] As used in the present invention, the terms "combination therapy", "combination therapy" and "co-therapy" are used interchangeably and generally refer to a treatment method characterized by a recombinant fusion protein or a pharmaceutical composition comprising a recombinant fusion protein provided by the present invention and an additional therapeutic agent. Typically, a combination therapy is intended to be part of a specific treatment regimen that provides a beneficial effect from the combined action of a combination of therapeutic agents. The beneficial effects of the combination may include, but are not limited to, pharmacokinetic or pharmacodynamic synergy produced by a combination of therapeutic agents. The combined administration of these therapeutic agents is usually carried out within a specified time period (depending on the selected combination, usually minutes, hours, days or weeks). In some embodiments, the combination therapy includes administering two or more therapeutic agents in a sequential manner, wherein each therapeutic agent is administered at different times, and administering these therapeutic agents or at least two therapeutic agents in a substantially simultaneous manner. Substantially simultaneous administration can be achieved, for example, by administering to a subject a single dosage form of each therapeutic agent having a fixed ratio or a plurality of separate dosage forms of the therapeutic agent. Sequentially or substantially simultaneously administering each therapeutic agent can be achieved by any appropriate route, including but not limited to oral routes, intravenous routes, intramuscular routes, and direct absorption via mucosal tissue. The therapeutic agents can be administered by the same route or by different routes. The therapeutic agents can be administered at the same or different dosing intervals. For example, the first therapeutic agent of the selected combination can be administered by intravenous injection, while the other therapeutic agents of the combination can be administered orally. Alternatively, for example, all therapeutic agents can be administered orally or all therapeutic agents can be administered by intravenous injection.
[0201] In some embodiments, the combination therapy also encompasses the further combined administration of therapeutic agents as described above with other biologically active ingredients and non-drug therapies (e.g., surgery or radiation therapy). Where the combination therapy further comprises non-drug therapy, the non-drug therapy may be performed at any suitable time, as long as the synergistic effect of the combination of the therapeutic agent and the non-drug therapy achieves a beneficial effect. For example, in appropriate cases, when the non-drug therapy is temporarily removed from the administration of the therapeutic agent (perhaps for several days or even weeks), a beneficial effect is still achieved.
[0202] In some embodiments, the additional therapeutic agent is a chemotherapeutic agent (also known as an anti-neoplastic agent or anti-proliferative agent), for example, an alkylating agent; an antibiotic; an antimetabolite; an antidote; an interferon; a polyclonal or monoclonal antibody; an EGFR inhibitor; a HER2 inhibitor; a histone deacetylase inhibitor; a hormone; a mitotic inhibitor; an MTOR inhibitor; a multikinase inhibitor; a serine / threonine kinase inhibitor; a tyrosine kinase inhibitor; a VEGF / VEGFR inhibitor; a taxane or a taxane derivative, an aromatase inhibitor, an anthracycline, a microtubule-targeted drug, a topoisomerase poison, an inhibitor of a molecular target or enzyme (e.g., a kinase or protein methyltransferase), a cytidine analog drug, or any chemotherapeutic agent, an immune checkpoint inhibitor, a platinum anti-neoplastic agent, a CDK inhibitor, a PARP inhibitor, or any anti-neoplastic agent or anti-proliferative agent known to those skilled in the art.
[0203] Exemplary alkylating agents suitable for use in the combination therapy provided herein include, but are not limited to, cyclophosphamide (Cytoxan; Neosar); chlorambucil (Leukeran); melphalan (Alkeran); carmustine (BiCNU); busulfan (Busulfex); lomustine (CeeNU); dacarbarin (DTIC-Dome); oxaliplatin (Eloxatin); carmustine (Gliadel); ifosfamide (Ifex); mustargen; busulfan (Myleran); carboplatin (Paraplatin); cisplatin (CDDP; Platinol); temozolomide (Temodar); thiotepa (Thioplex); bendamustine (Treanda); or streptozocin (Zanosar).
[0204] Exemplary suitable anthracyclines include, but are not limited to, Adriamycin; Doxil; Novantrone; Blenoxane; Cerubidine; Daunoxome; Cosmegen; Ellence; Idamycin; Mithracin; Mutamycin; Nipent; or Valstar.
[0205] Exemplary antimetabolites include, but are not limited to, fluorouracil (Adrucil); capecitabine (Xeloda); hydroxyurea (Hydrea); mercaptopurine (Purinethol); pemetrexed (Alimta); fludarabine (Fludara); nelarabine (Arranon); cladribine (Cladribine Novaplus); clofarabine (Clolar); cytarabine (Cytosar-U); decitabine (Dacogen); cytarabine liposome (DepoCyt); hydroxyurea (Droxia); pralatrexate (Folotyn); floxuridine (FUDR); gemcitabine (Gemzar); cladribine (Leustatin); fludarabine (Oforta); methotrexate (MTX; Rheumatrex); methotrexate (Trexall); thioguanine (Tabloid); TS-1 or cytarabine (Tarabine PFS).
[0206] Exemplary antidotes include, but are not limited to, amifostine (Ethyol) or mesna (Mesnex).
[0207] Exemplary interferons include, but are not limited to, interferon alpha-2b (Intron A) or interferon alpha-2a (Roferon-A).
[0208] Exemplary polyclonal or monoclonal antibodies include, but are not limited to, trastuzumab (Herceptin); ofatumumab (Arzerra); bevacizumab (Avastin); rituximab (Rituxan); cetuximab (Erbitux); panitumumab (Vectibix); tositumomab / iodine-131 tositumomab (Bexxar); alemtuzumab (Campath); ibritumomab tiuxetan (Zevalin; In-111; Y-90Zevalin); gemtuzumab (Mylotarg); eculizumab (Soliris) or denosumab.
[0209] Exemplary EGFR inhibitors include, but are not limited to, gefitinib (Iressa); lapatinib (Tykerb); cetuximab (Erbitux); erlotinib (Tarceva); panitumumab (Vectibix); PKI-166; canertinib (CI-1033); matuzumab (EMD 72000), or EKB-569.
[0210] Exemplary HER2 inhibitors include, but are not limited to, trastuzumab (Herceptin); lapatinib (Tykerb) or AC-480.
[0211] Histone deacetylase inhibitors include, but are not limited to, vorinostat (Zolinza).
[0212] Exemplary sex hormones include, but are not limited to, tamoxifen (Soltamox; Nolvadex); raloxifene (Evista); megestrol acetate (Megace); leuprolide (Lupron; Lupron Depot; Eligard; Viadur); fulvestrant (Faslodex); letrozole (Femara); triptorelin (Trelstar LA; Trelstar Depot; exemestane (Aromasin); goserelin (Zoladex); bicalutamide (Casodex); anastrozole (Arimidex); fluoxymesterone (Androxy; Halotestin); medroxyprogesterone (Provera; Depo-Provera); estramustine (Emcyt); flutamide (Eulexin); toremifene (Fareston); degarelix (Firmagon); nilutamide (Nilandron); abarelix (Plenaxis); or testolactone (Teslac).
[0213] Exemplary mitotic inhibitors include, but are not limited to, paclitaxel (Taxol; Onxol; Abraxane); docetaxel (Taxotere); vincristine (Oncovin; Vincasar PFS); vinblastine (Velban); etoposide (Toposar; Etopophos; VePesid); teniposide (Vumon); ixabepilone (Ixempra); nocodazole; epothilone; vinorelbine (Navelbine); camptothecin (CPT); irinotecan (Camptosar); topotecan (Hycamtin); amsacrine or lamellaemin D (LAM-D).
[0214] Exemplary MTOR inhibitors include, but are not limited to, everolimus (Afinitor) or temsirolimus (Torisel); rapamune, riboflavin; or AP23573.
[0215] Exemplary multi-kinase inhibitors include, but are not limited to, sorafenib (Nexavar); sunitinib (Sutent); BIBW2992; E7080; Zd6474; PKC-412; motesanib; or AP24534.
[0216] Exemplary serine / threonine kinase inhibitors include, but are not limited to, rubustard; oerel / fasudil hydrochloride; flavopiridol; celecoxib (CYC202; Roscovitine); SNS-032 (BMS-387032); Pkc412; bryostatin; KAI-9803; SF1126; VX-680; Azd1152; Arry-142886 (AZD-6244); SCIO-469; GW681323; CC-401; CEP-1347 or PD 332991.
[0217] Exemplary tyrosine kinase inhibitors include, but are not limited to, erlotinib (Tarceva); gefitinib (Iressa); imatinib (Gleevec); sorafenib (Nexavar); sunitinib (Sutent); trastuzumab (Herceptin); bevacizumab (Avastin); rituximab (Rituxan); lapatinib (Tykerb); cetuximab (Erbitux); panitumumab (Vectibix); everolimus (Afinitor); alemtuzumab (Campath); gemtuzumab (Mylotarg); temsirolimus (Torisel); pazopanib (Votrient); dasatinib (Sprycel); nilotinib (Tasigna); vatalanib (Ptk787; ZK222584); CEP-701; SU5614; MLN518; XL999; VX-322; Azd0530; BMS-354825; SKI-606CP-690; AG-490; WHI-P154; WHI-P131; AC-220; or AMG888.
[0218] Exemplary VEGF / VEGFR inhibitors include, but are not limited to, bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent), ranibizumab, pegatinib, or vandetinib.
[0219] Exemplary microtubule-targeting drugs include, but are not limited to, paclitaxel, docetaxel, vincristine, vinblastine, nocodazole, epothilone, and vinpoline.
[0220] Exemplary topoisomerase poisons include, but are not limited to, teniposide, etoposide, doxorubicin, camptothecin, daunomycin, dactinomycin, mitoxantrone, amsacrine, epirubicin, and idarubicin.
[0221] Exemplary taxanes or taxane derivatives include, but are not limited to, paclitaxel and docetaxel.
[0222] Exemplary immune checkpoint inhibitors include programmed cell death 1 (PD-1), CD274 molecule (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA4) inhibitors. Exemplary PD-1 inhibitors include pembrolizumab, nivolumab, and cemiplimab. Exemplary PD-L1 inhibitors include atezolizumab, avelumab, and durvalumab. Exemplary CLTA4 inhibitors include ipilimumab.
[0223] Exemplary platinum anti-tumor agents include cisplatin and carboplatin.
[0224] Exemplary cyclin-dependent kinase (CDK) inhibitors include abemaciclib, palbociclib, and ribociclib.
[0225] Exemplary poly (ADP-ribose) polymerase (PARP) inhibitors include talazopari, olaparib, rucaparib, niraparib, and veliparib.
[0226] Exemplary general chemotherapeutic agents, anti-tumor agents, anti-proliferative agents include, but are not limited to, hexamethylmelamine (Hexalen); isotretinoin (Accutane; Amnesteem; Claravis; Sotret); tretinoin (Vesanoid); azacitidine (Vidaza); bortezomib (Velcade); asparaginase (Elspar); levamisole (Ergamisol); mitotane (Lysodren); procarbazine (Matulane) ; pegaspargase (Oncaspar); denileukin (Ontak); porphin (Photofrin); aldesleukin (Proleukin); lenalidomide (Revlimid); bexarotene (Targretin); thalidomide (Thalomid); temsirolimus (Torisel); arsenic trioxide (Trisenox); verteporfin (Visudyne); mimosapine (Leucenol); (1M fluazifop-0.4M 5-chloro-2,4-dihydroxypyridine-1M potassium oxadiazine) or lovastatin.
[0227] In some embodiments, a combination therapy is provided, wherein the additional therapeutic agent is a cytokine, such as G-CSF (granulocyte colony stimulating factor). In another aspect, the pharmaceutical composition provided by the present invention can be administered in combination with radiotherapy. Radiotherapy can also be administered in combination with the pharmaceutical composition provided by the present invention and another chemotherapeutic agent described in the present invention as part of a multi-agent therapy. In another aspect, the pharmaceutical composition provided by the present invention can be administered in combination with standard chemotherapy, such as but not limited to CMF (cyclophosphamide, methotrexate and 5-fluorouracil), CAF (cyclophosphamide, doxorubicin and 5-fluorouracil), AC (doxorubicin and cyclophosphamide), FEC (5-fluorouracil, epirubicin and cyclophosphamide), ACT or ATC (doxorubicin, cyclophosphamide and paclitaxel), rituximab, Xeloda (capecitabine), cisplatin (CDDP), carboplatin, TS-1 (flunisal, gimeratin and ortalast potassium, molar ratio of 1:0.4:1), camptothecin-11 (CPT-11, irinotecan or Camptosar TM ), CHOP (cyclophosphamide, hydroxydaunomycin, enclosing and pralidone or pralidone), R-CHOP (rituximab, cyclophosphamide, hydroxydaunomycin, enclosing, pralidone or pralidone) or CMFP (cyclophosphamide, methotrexate, 5-fluorouracil and pralidone).
[0228] In some preferred embodiments, the pharmaceutical composition provided by the present invention can be administered together with an inhibitor of an enzyme (such as a receptor or non-receptor kinase). Receptor and non-receptor kinases are, for example, tyrosine kinases or serine / threonine kinases. The kinase inhibitors described in the present invention are small molecules, polynucleic acids, polypeptides or antibodies.
[0229] Exemplary kinase inhibitors include, but are not limited to, bevacizumab (targeting VEGF), BIBW 2992 (targeting EGFR and Erb2), cetuximab / Erbitux (targeting Erb1), imatinib / Gleevec (targeting Bcr-Abl), trastuzumab (targeting Erb2), gefitinib / Iressa (targeting EGFR), ranibizumab (targeting VEGF), pegatinib (targeting VEGF), erlotinib / Tarceva (targeting Erb1), nilotinib (targeting Bcr-Abl), lapatinib (targeting Erb1 and Erb2 / Her2), GW-572016 / lapatinib ditosylate (targeting HER2 / Erb2), panitumumab / Vectibix (targeting EGFR), vandetinib (targeting RET / VEGFR), E7080 (multi-target, including RET and VEGFR), Herceptin (targeting HER2 / Erb2), PKI-166 (targeting EGFR), canertinib / CI-1033 (targeting EGFR), sunitinib / SU-11464 / Sutent (targeting EGFR and FLT3), matuzumab / Emd7200 (targeting EGFR), EKB-569 (targeting EGFR), Zd6474 (targeting EGFR and VEGFR), PKC-412 (targeting VEGR and FLT3), vatalanib / Ptk787 / ZK222584 (targeting VEGR), CEP-701 (targeting FLT3), SU5614 (targeting FLT3), MLN518 (targeting FLT3), XL999 (targeting FLT3), VX-322 (targeting FLT3), Azd0530 (targeting SRC), BMS-354825 (targeting SRC), SKI-606 (targeting SRC), CP-690 (targeting JAK), AG-490 (targeting JAK), WHI-P154 (targeting JAK), WHI-P131 (targeting JAK) , sorafenib / Nexavar (targeting RAF kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, KIT, FLT-3 and RET), dasatinib / Sprycel (BCR / ABL and Src), AC-220 (targeting Flt3), AC-480 (targeting all HER proteins, "panHER"), motesanib diphosphate (targeting VEGF1-3, PDGFR and c-kit), denosumab (targeting RANKL, inhibiting SRC), AMG888 (targeting HER3) and AP24534 (multi-target, including Flt3).
[0230] In some embodiments, such as those embodiments where a recombinant fusion protein is administered to treat atrial fibrillation, the combination therapy may include administering a beta blocker (e.g., bisoprolol or metoprolol succinate), a calcium channel blocker (e.g., diltiazem or verapamil), digoxin, an antiarrhythmic drug (e.g., propafenone, flecainide, sotalol, dofetilide, amiodarone, and dronedarone), or a blood thinner (e.g., warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban). In some embodiments, the combination therapy may include cardioversion therapy to reset the heart's sinus rhythm (e.g., electrical or drug cardioversion). In some embodiments, the combination therapy may include ablation, such as AV node ablation or Maze surgery. Ablation uses a scalpel, heat therapy, or cold therapy to form a small scar on the heart, blocking erroneous electrical signals and restoring normal heart rhythm.
[0231] In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide disclosed in the present invention is administered to a subject once a day. In some embodiments, a recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject once every two days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject once every three days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject once every four days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject once every five days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject once every six days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject once a week. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject once every 7-14 days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject once every 10-20 days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject once every 5-15 days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject once every 15-30 days.
[0232] In one embodiment, the dosage of the recombinant fusion protein of the present invention comprises 0.005 to 0.1 mg / kg in an injectable solution. In another embodiment, the dosage comprises 0.005 to 0.5 mg / kg of the recombinant fusion protein. In another embodiment, the dosage comprises 0.05 to 0.1 micrograms of the recombinant fusion protein. In another embodiment, the dosage comprises 0.005 to 0.1 mg / kg of the recombinant fusion protein in an injectable solution.
[0233] In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage in the range of 0.0001 mg to 0.6 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage in the range of 0.001 mg to 0.005 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage in the range of 0.005 mg to 0.01 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage in the range of 0.01 mg to 0.3 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage in the range of 0.2 mg to 0.6 mg.
[0234] In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 1-100mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 10-80mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 20-60mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 10-50mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 40-80mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 10-30mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 30-60mcg / kg.
[0235] In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 0.1mcg / kg to 100mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 0.1mcg / kg to 50mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 0.1mcg / kg to 25mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 0.1mcg / kg to 10mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 0.1mcg / kg to 5mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 0.1mcg / kg to 1mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 0.1mcg / kg to 0.1mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose ranging from 10 mg / kg to 60 mg / kg.
[0236] In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 20 mg / kg, about 30 mg / kg, about 40 mg / kg, about 50 mg / kg, about 60 mg / kg or about 70 mg / kg. In some embodiments, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg or 1 mg / kg.
[0237] In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage in the range of 0.2 mg to 2 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage in the range of 2 mg to 6 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage in the range of 4 mg to 10 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage in the range of 5 mg to 15 mg.
[0238] In one embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 10 μg / kg-1000 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 25 μg / kg-600 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage within the range of 50 μg / kg-400 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage of about 25 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage of about 50 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage of about 100 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage of about 200 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising it is administered to a subject at a dosage of about 300 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 400 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 500 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 600 μg / kg.
[0239] In one embodiment, a single dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject. In another embodiment, a total of two doses are administered to the subject. In another embodiment, a total of two or more doses are administered to the subject.
[0240] In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject at least once a day. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject at least once every two days. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject at least once every two days or more. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject weekly, every two weeks or every three weeks. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject at least once a week. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject at least once every two weeks. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject at least once every three weeks. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject at least once every three weeks or more weeks. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject twice or more per week. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject twice or more per month. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject twice or more per year. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject twice or more every two years. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject twice or more every two years or more.
[0241] In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 36 hours. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 48 hours. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 60 hours. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 72 hours. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 84 hours. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 96 hours. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 5 days. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 6 days. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 7 days. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 8-10 days. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 10-12 days. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 12-15 days. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 15-25 days. In another embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 20-30 days.
[0242] In one embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered to the subject at least once every 1 month. In one embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 2 months. In one embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 3 months. In one embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 4 months. In one embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 5 months. In one embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 6 months. In one embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered at least once every 6-12 months. In one embodiment, the dose of the recombinant fusion protein or a pharmaceutical composition comprising it is administered quarterly. In another embodiment, the dose is administered daily, weekly, biweekly, monthly or annually. In another embodiment, the dose is administered once, twice or more in one day, one week, one month or one year. In another embodiment, the dose is administered every two years, three years, four years or at least five years.
[0243] In one embodiment, repeated administration (dosing) of the composition of the present invention can be carried out immediately after the first course of treatment, or after an interval of several days, weeks or years, to achieve the desired effect further provided by the present invention (e.g., prevention or treatment of cardiovascular diseases or conditions, or CNS-related diseases or conditions).
[0244] In one embodiment, the pharmaceutical composition is administered by intravenous, intraarterial, subcutaneous or intramuscular injection of a liquid formulation. In another embodiment, the liquid formulation comprises a solution, a suspension, a dispersion, an emulsion, an oil and the like. In one embodiment, the pharmaceutical composition is administered intravenously and is therefore formulated in a form suitable for intravenous administration. In another embodiment, the pharmaceutical composition is administered intraarterially and is therefore formulated in a form suitable for intraarterial administration.
[0245] In some embodiments, the compositions used in the methods disclosed herein comprise solutions or emulsions, which in some embodiments are aqueous solutions or emulsions comprising a safe and effective amount of a compound disclosed herein and optionally other compounds, intended for intravenous or subcutaneous administration.
[0246] In some embodiments, the various components of the composition are pre-measured and / or pre-packaged and / or used without additional measurement, etc. The present invention also optionally includes a kit for performing / using the method and / or composition of the present invention. In particular, these kits optionally include, for example, suitable recombinant fusion proteins (and optionally a mixture of several such proteins, for synergistic therapy, see above) and optionally suitable disease-related antigens). In addition, such kits may also include suitable excipients (e.g., pharmaceutically acceptable excipients) for therapeutic and / or preventive treatments of the present invention. Such kits optionally contain additional components for assembling and / or using the composition of the present invention, including, but not limited to, for example, diluents, etc.
[0247] The compositions described herein are optionally packaged to include all (or substantially all) of the necessary components for performing the methods of the invention or for using the compositions of the invention (optionally including, for example, written instructions for use of the methods / compositions of the invention). For example, kits optionally include components such as buffers, reagents, serum proteins, antibodies, substrates, etc. In the case of prepackaged reagents, the kits optionally include pre-measured or pre-dosed amounts that can be incorporated into the method without measurement, such as pre-measured aliquots of fluids; or pre-weighed or pre-measured solid reagents that can be easily reconstituted by the end user of the kit.
[0248] Such kits also typically include appropriate instructions for performing the methods of the present invention and / or using the compositions of the present invention. In some embodiments, the components of the kit / package are provided in a stable form to prevent degradation or other losses, such as leakage, during long-term storage. Various stabilization methods / agents are widely used for reagents to be stored, etc., such as chemical stabilizers (i.e., enzyme inhibitors, microbicides / bacteriostatics, anticoagulants), etc. The actual dosage concentration of the active ingredient in the pharmaceutical composition of the present invention may vary so as to obtain a certain amount of active ingredient that is effective in achieving the desired therapeutic response of a specific subject, composition, and administration method without being toxic to the subject. The selected dosage concentration will depend on a variety of pharmacokinetic factors, including the activity of the specific composition of the present invention used; route of administration; time of administration; excretion rate of the specific compound used; duration of treatment; other drugs, compounds, and / or substances used in combination with the specific composition used; age, sex, weight, condition, general health, and previous medical history of the subject being treated; and similar factors well known in the medical field.
[0249] The composition must be sterile and fluid to the extent that the composition can be delivered by a syringe. In addition to water, the carrier is preferably an isotonic buffered saline solution. For example, appropriate fluidity can be maintained by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersion, and by using a surfactant. In many cases, it is preferred to include an isotonic agent, such as a sugar, a polyol (such as mannitol or sorbitol), and sodium chloride in the composition.
[0250] The actual dosage concentration of the active ingredient in the pharmaceutical composition of the present invention may be varied so as to obtain an amount of active ingredient that is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration without being toxic to the subject. The selected dosage concentration will depend on a variety of pharmacokinetic factors, including the activity of the particular composition of the present invention employed; the route of administration; the time of administration; the rate of excretion of the particular compound employed; the duration of treatment; other drugs, compounds, and / or substances used in combination with the particular composition employed; the age, sex, weight, condition, general health, and previous medical history of the subject being treated; and similar factors well known in the medical field.
[0251] Although the present invention has described and shown several embodiments of the present invention, a person of ordinary skill in the art will readily conceive of various other methods and / or structures to perform the functions and / or obtain the results and / or one or more of the advantages described in the present invention, and each of such changes and / or modifications is considered to be within the scope of the embodiments of the present invention described in the present invention. More generally, it will be readily understood by those skilled in the art that all parameters, dimensions, materials and configurations described in the present invention are intended to be exemplary, and actual parameters, dimensions, materials and / or configurations will depend on the specific application or application used / used by the teachings of the present invention. A person skilled in the art will recognize or be able to determine many equivalents of the specific embodiments of the invention described herein using only routine experiments. Therefore, it should be understood that the foregoing embodiments are presented only as embodiments and in the scope of the claims attached thereto and their equivalents, and embodiments of the present invention may not be implemented as specifically described and claimed. The inventive embodiments of the present invention are about the various features, systems, articles, materials, kits and / or methods described in the present invention. In addition, any combination of two or more such features, systems, articles, materials, kits and / or methods is included within the scope of the present invention when such features, systems, articles, materials, kits and / or methods are not mutually inconsistent.
[0252] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.
[0253] All references, patents, and patent applications disclosed herein are incorporated by reference for the subject matter for which they are cited, and in some cases may be incorporated in their entirety.
[0254] Unless expressly indicated to the contrary, the indefinite articles "a" and "an" as used in the present specification and claims should be understood to mean "at least one".
[0255] The phrase "and / or" as used in the specification and claims of the present invention should be understood to refer to "any or both" of the elements so combined (i.e., elements that exist in combination in some cases and separately in other cases). Multiple elements listed using "and / or" should be interpreted in the same manner, that is, "one or more" elements so combined. In addition to the elements specifically identified by the "and / or" clause, other elements may optionally be present, whether related or unrelated to those specifically identified elements. Thus, as a non-limiting example, a reference to "A and / or B", when used in conjunction with an open-ended phrase such as "comprising", may refer to A alone (optionally including elements other than B) in one embodiment; to B alone (optionally including elements other than A) in another embodiment; to both A and B (optionally including other elements) in another embodiment; etc.
[0256] As used in the specification and claims, the phrase "at least one" when referring to a list of one or more components should be understood to refer to at least one component selected from any one or more components in the list of components, but does not necessarily include at least one of each component specifically listed in the list of components and does not exclude any combination of components in the list of components. This definition also allows that elements other than the elements specifically identified in the list of elements referred to by the phrase "at least one" may optionally be present, whether related or unrelated to the specifically identified elements. Thus, as a non-limiting example, "at least one A and B" (or equivalently "at least one A or B" or equivalently "at least one A and / or B") may refer to at least one (optionally including more than one) A without B (and optionally including elements other than B) in one embodiment; to at least one (optionally including more than one) B without A (and optionally including elements other than A) in another embodiment; to at least one (optionally including more than one) A and at least one (optionally including more than one) B (and optionally including other elements) in yet another embodiment; and so on.
[0257] The present invention further provides a kit for preventing, treating or delaying cardiovascular diseases or conditions in humans, wherein the kit comprises one or more doses of a pharmaceutical composition comprising the recombinant fusion protein disclosed in the present invention, for preventing, treating or delaying cardiovascular diseases or conditions, and instructions on how to use the pharmaceutical preparation or composition.
[0258] The present invention further provides a kit for preventing, treating or delaying CNS-related diseases or conditions in humans, wherein the kit comprises one or more doses of a pharmaceutical composition comprising the recombinant fusion protein disclosed in the present invention, for preventing, treating or delaying cardiovascular diseases or conditions, and instructions on how to use the pharmaceutical preparation or composition.
[0259] The present invention further provides a drug kit for preventing, treating or delaying heart failure with preserved ejection fraction in humans, wherein the drug kit comprises one or more doses of a pharmaceutical composition comprising the recombinant fusion protein disclosed in the present invention, for preventing, treating or delaying heart failure with preserved ejection fraction, and instructions on how to use the pharmaceutical preparation or composition.
[0260] The following examples are provided to more fully illustrate the preferred embodiments of the invention. However, they should not be construed in any way as limiting the broad scope of the invention. Example Example 1 - Cloning and construction of expression plasmids
[0261] The DNA sequences encoding the heavy chain (named NPCFA and NPCF, indicating the sequence with or without Fc mutation, respectively) and light chain (named PAL) of the recombinant fusion protein were synthesized by GENEWIZ (Suzhou, China). The expression vector pCHOGUN was obtained from Horizon Discovery (Cambridge, UK) under a license agreement. The construction of the expression plasmids was as follows Figure 1 The pCHOGUN vector was linearized by restriction enzyme BfuAI and purified after double restriction enzyme digestion by NcoI and AscI, such as NPCF, NPCFA and PAL. Linearized pCHOGUN / BfuAI and purified gene inserts were connected according to standard protocols and then transformed into E. coli DH5α competent cells. DH5α cells were inoculated and incubated overnight at 37°C. Plasmids pCHOGUN-NPCF, pCHOGUN-NPCFA and pCHOGUN-PAL were isolated and confirmed by restriction enzyme digestion or PCR. Plasmids containing heavy chain inserts (pCHOGUN-NPCF or pCHOGUN-NPCFA) were digested with restriction enzymes BspEI and PciI, while plasmids containing light chain inserts (pCHOGUN-PAL) were digested with restriction enzymes NgoMIV and PciI. After restriction enzyme digestion, the fragments with heavy or light chain inserts were purified, ligated and subsequently transformed into DH5α cells. Plasmid constructs (pCHOGUN-NPCF+PAL or pCHOGUN-NPCFA+PAL) containing heavy and light chain inserts were identified and confirmed by restriction enzyme digestion and DNA sequencing. Example 2 - Antibody Production, Purification and Characterization
[0262] HD-BIOP3, a glutamine synthetase-deficient (GS) - / - ) cell line, obtained from Horizon Discovery (Cambridge, UK) under a license agreement. Plasmid DNA was isolated using a commercially available Qiagen plasmid kit. Plasmid DNA was transfected into HD-BIOP3 cells using a commercially available electroporation system from Lonza. Transfected cells were seeded in 96-well plates and pool selection was performed using standard procedures. Cells from the selected pools were cultured in 125-mL shake flasks for 10-14 days, and the culture medium was harvested for antibody purification. Antibody protein was purified by protein A affinity chromatography, followed by size exclusion chromatography purification, and then analyzed by SDS-PAGE and Western blot according to standard protocols.
[0263] Figure 2A The schematic structure of the recombinant fusion protein disclosed in the present invention is shown. Figure 2BRepresentative data generated by SDS-PAGE analysis are shown. Western blot results detected by a primary antibody specific for a 61 amino acid active fragment of NRG-1 containing the HER3 / 4 binding domain ("NRG-1", R&D Systems, Minneapolis, MN) or a primary antibody specific for IgG are shown in Figure 2C and 2D middle. Example 3 - Assessment of molecular integrity by SPR-based binding analysis
[0264] The molecular structural integrity of the recombinant fusion protein disclosed in the present invention is assessed by evaluating its ability to simultaneously bind to HER3 protein and anti-NRG-1 antibody. The His-tagged HER3 recombinant protein (Sino Biological, Beijing, China) was captured on a sensor chip immobilized with an anti-His antibody (Thermo Fisher, Waltham, MA) (step 1), and then the sample (including the recombinant fusion protein disclosed in the present invention, the recombinant fusion protein disclosed in the present invention without Fc mutation, anti-HER3 mAb (step 2), and anti-NRG-1 antibody (R&D Systems, Minneapolis, MN) (step 3) was injected. The attachment of His-HER3 to the sensor chip can be visualized by the increase in signal on all 6 channels in step 1. The recombinant fusion protein disclosed in the present invention and the recombinant fusion protein disclosed in the present invention without Fc mutation both produced significant responses by binding to HER3 in step 2 and by binding to the injected anti-NRG-1 antibody in step 3 (Ch1, 3), indicating the presence of HER3 binding epitopes and NRG-1 on the recombinant fusion protein disclosed in the present invention. In contrast, the anti-HER3 The mAb only binds to His-HER3 in step 2, but not to the anti-NRG-1 antibody and buffer (step 3) (Ch 4, 5), thereby verifying that the anti-HER3 mAb molecule has no NRG-1 binding activity. The buffer was injected as a blank control in steps 2 and 3. Therefore, both the HER3 binding epitope and NRG-1 are present in the recombinant fusion protein of the present invention.
[0265] The combined sensor diagram and sample injection sequence are shown in Figure 3 middle. Example 4 - Effect on proliferation of tumor cell lines in vitro
[0266] Tumor cells were seeded in 96-well plates at 2,500-20,000 cells per well, depending on the growth kinetics of each cell line. Cells were then treated with the recombinant fusion proteins, antibodies, or control proteins disclosed in the present invention at a stepwise 1:4 serial dilution for 5 days. Cell viability was assessed using a cell counting kit-8 from Dojindo Molecular Technologies (Kumamoto, Japan) according to the manufacturer's instructions. Data were analyzed using GraphPad Prism software and expressed as growth rate relative to untreated controls.
[0267] Figure 4 includes representative graphs showing the mean relative growth rate ± SEM (n=3) of different cancer cell lines: (A) NCI-N87, stomach; (B) MCF-7, breast; (C) RT-112, bladder; and (D) T47D, breast. Compared with the control NRG-1 and GP120 mAb / NRG-1 fusion proteins, the recombinant fusion proteins disclosed in the present invention exhibit significantly lower activity in promoting cancer cell proliferation. Example 5 - Activation of the PI3K / AKT signaling pathway in human cardiomyocytes
[0268] Human cardiomyocytes obtained from Cellular Dynamics (Madison, WI) were seeded in 96-well plates coated with 0.1% gelatin and recovered in plating medium (Cellular Dynamics) for 4 hours. The cells were then cultured in maintenance medium (Cellular Dynamics) for 96 hours before being used in experiments. To test the ability of the recombinant fusion protein of the present invention to activate the HER2:HER4 signaling pathway in cardiomyocytes, the cells were first starved for 4 hours in serum-free medium, and then treated with recombinant fusion protein or control agent (NRG-1, GP120 mAb / NRG-1, anti-HER3 mAb or GP120 mAb) for 15 minutes in a stepwise 1:4 serial dilution. At the end of the treatment, the cells were lysed and AKT phosphorylation was analyzed using Abcam's phospho-AKT / total AKT ELISA kit (Cambridge, MA) according to the manufacturer's instructions. The data were analyzed with GraphPad Prism software and expressed as the ratio of phospho-AKT to total AKT relative to the untreated control.
[0269] For Western blot analysis, cells were seeded in 6-well plates and treated with a single concentration of 16 nM of the recombinant fusion protein of the present invention or a control agent. At the end of the treatment, cells were lysed in RIPA lysis buffer containing protease and phosphatase inhibitors. SDS-PAGE and Western blotting were performed according to standard protocols. Total AKT and phospho-AKT were blotted with AKT rabbit antibody and p-AKT (S473) rabbit antibody (Cell Signaling; Danvers, MA), respectively.
[0270] Figure 5 shows AKT phosphorylation in human cardiomyocytes in response to stimulation. The results show that the recombinant fusion protein disclosed in the present invention can activate the HER2:HER4 signaling pathway in cardiomyocytes with an efficacy comparable to that of NRG-1. Example 6: Induction of HER2:HER3 dimerization and HER2:HER4 dimerization
[0271] The PathHunter Dimerization Assay developed by Eurofins DiscoverX (Fremont, CA) detects ligand-induced dimerization of the two subunits of the receptor-dimer pair. The assay principle is shown in Fig. 6A The β-gal enzyme is divided into two fragments, namely ProLink (PK) and enzyme receptor (EA). Cells are engineered to co-express target protein 1 fused to the enzyme donor PK and target protein 2 fused to the enzyme receptor EA. The binding of the ligand to one target protein induces its interaction with the other target protein, forcing the two enzyme fragments to complement each other and resulting in the enzyme reaction releasing a chemiluminescent signal, which is detected in relative fluorescence units or RFU.
[0272] PathHunter U2OS ErbB2 / ErbB4 dimerization cell line and ErbB2 / ErbB3 dimerization cell line were obtained from Eurofins DiscoverX. Cells were seeded at 4,000 cells / well in 384-well plates and incubated overnight at 37°C / 5% CO2. Test agents were prepared in a stepwise 1:4 serial dilution series starting from 28.8 nM and then added to the cells in 384-well plates. After 4 hours of incubation, cells were analyzed for receptor dimerization according to the manufacturer's instructions. Data were analyzed with GraphPad Prism software and are presented as mean RFU±SEM (n=3).
[0273] like Figure 6B and 6CAs shown, the recombinant fusion protein disclosed in the present invention can induce HER2 / HER4 dimerization, and its potency is comparable to that of NRG-1; while its ability to induce HER2 / HER3 dimerization is much weaker. As negative controls of the study, the isotype control antibody GP120 mAb and anti-HER3 mAb did not induce receptor dimerization.
[0274] Having described the embodiments of the present invention by referring to the accompanying drawings, it should be understood that the present invention is not limited to the precise embodiments and that various changes and modifications may be made therein by one skilled in the art without departing from the scope or spirit of the present invention as defined in the appended claims. Example 7: In vivo efficacy of recombinant fusion protein in a rat model of systolic heart failure
[0275] To evaluate the ability of the recombinant fusion protein to restore cardiac function in a disease model, the Sprague Dawley rat model of myocardial infarction and systolic heart failure was used. To establish the disease model, the left anterior descending coronary artery (LAD) was ligated 3-4 mm below the left atrial appendage using a 6-0 silk suture during surgery. Four weeks after ligation, the ejection fraction (EF) was recorded by M-mode echocardiography (ECG) Doppler ultrasound to measure cardiac function relative to the baseline EF before surgery. When included in the subsequent study, a minimum EF threshold of 30% decrease was used. Sham control animals underwent the same surgery, but without LAD ligation.
[0276] After the disease model was established, the animals were divided into five groups of eleven rats each, and ten sham-operated rats were in the sixth group. The study design was that each group received two tail vein injections per week for four weeks, or a total of eight injections. The sham-operated group and the negative control vehicle group all received normal saline, three groups received 1, 3 or 10 mg / kg of the recombinant fusion protein, and the last group received the positive control GP120 mAb / NRG-1 fusion protein (10 mg / kg).
[0277] Due to weight loss observed during the study, treatment was stopped before the full sequence of eight injections in the groups receiving 3 mg / kg and 10 mg / kg of the recombinant fusion protein, which received only six and three injections, respectively. All other groups received the full eight injections.
[0278] Four weeks after the first treatment, EF was measured again by M-mode ECG. Figure 8As shown, the recombinant fusion protein significantly increased EF in all three dose groups relative to baseline. Specifically, increases of 14.7% (P<0.001), 26.9% (P<0.001), and 36.6% (P<0.001) were observed in the 1, 3, and 10 mg / kg groups, respectively. The GP120 mAb / NRG-1 positive control increased EF by 28.8% (P<0.001) at the matched time points. Saline showed no effect in either the sham or vehicle control groups.
[0279] After collecting ECG values 28 days after treatment, mice were euthanized, and heart tissues next to the surgical site were collected, fixed in 4% formaldehyde, and embedded in paraffin. Five-micrometer-thick paraffin sections of heart tissues were stained with hematoxylin and eosin dyes, and histopathological changes were observed under an optical microscope. Figures 9A-9F As shown, in the sham group, cardiomyocytes were arranged in an orderly manner, and the cytoplasm and myocardial fibers were uniformly stained. No inflammatory cell infiltration was observed in the interstitial space, and no myocardial necrosis was found. In contrast, in the vehicle control group, the myocardial infarction edge zone showed widening of the gaps between cardiomyocytes; the nuclei were condensed and fragmented, and the myocardial fiber arrangement lost its orderly structure; the cell size increased and interstitial edema was noted. Treatment with the recombinant fusion protein partially alleviated the pathological changes in the myocardial infarction area, including a significant reduction in necrotic cells, narrowing of the interstitial space between cardiomyocytes, and restoration of the myocardial fiber arrangement to a normal structure. Example 8: Recombinant fusion protein attenuates tumor growth in the NOD / SCID mouse subcutaneous FaDu cancer xenograft model
[0280] To evaluate the potential risk of recombinant fusion proteins promoting tumor growth, in vivo studies were performed in a FaDu cancer xenograft model. NOD / SCID mice (Beijing AK Bio-Technology Co. Ltd.) were housed in an SPF facility at CrownBio International Research and Development Center (Beijing, China) according to institutional guidelines. All experiments were performed in accordance with the requirements of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and with the permission of the CrownBio IACUC Committee.
[0281] Female NOD / SCID mice aged 7-10 weeks were inoculated subcutaneously in the right flank with FaDu tumor cells (3×10 6 ). When the tumor reaches about 150mm 3 At 14:1, mice were randomly divided into 6 study groups, 8 animals in each group. Test samples were administered intravenously by tail vein injection twice a week for three consecutive weeks, for a total of 6 treatments. Tumor growth was monitored by caliper measurement. The study was terminated 21 days after treatment.
[0282] Tumor growth in response to different treatments is summarized in Fig.10 The anti-HER3 mAb at 10 mg / kg showed significant antitumor activity, with a tumor growth inhibition (TGI) of 93.5% at the end of the study (p<0.001 compared to the vehicle group). The recombinant fusion protein also showed statistically significant TGI at the end of the study: 19.2% at the 1 mg / kg dose (p=0.048 compared to the vehicle group) and 56.2% at the 10 mg / kg dose (p<0.001 compared to the vehicle group). The control molecule GP120 mAb / NRG-1 fusion protein did not show antitumor activity at either high or low doses. No animal deaths occurred during the study. Tumor-bearing mice tolerated all tested agents well. No significant weight loss was observed in any experimental group ( Fig.11 ). These data indicate that under conditions of active tumor growth in vivo, the recombinant fusion protein exhibited tumor growth inhibition in a dose-dependent manner and suggest that the risk of the recombinant fusion protein to enhance or accelerate tumor growth in vivo is lower than that of the native NRG-1 protein. Example 9: No significant gastrointestinal toxicity was observed in cynomolgus monkeys administered the recombinant fusion protein
[0283] It has been previously reported that in a phase I clinical study (NCT01258387) in which subjects received placebo or a single dose of cimaglermin (full-length recombinant NRG-1β3), nausea and diarrhea were the second and fourth most common treatment-emergent adverse events, occurring in 40% and 27% of the combined high-dose group, respectively (Lenihan et al. J Am Coll Cardiol Basic Trans Science. 2016; 1(7):576-86). Similarly, in a phase II study of a recombinant NRG-1 peptide fragment (neucardin), nausea was the most commonly observed treatment-related adverse event, occurring in 20% of the study subjects (Jabbour et al. European Journal of Heart Failure (2011) 13:83-92). Finally, in the second Phase 2 study of necardin (ChiCTR-TRC-00000414), published results showed that 48.4% of adverse events observed were gastrointestinal in nature, the most commonly observed type of adverse event in this study and were related to dose level (Gao et al. J Am Coll Cardiol 2010;55:1907-14).
[0284] Two studies were conducted to evaluate the safety and tolerability of the recombinant fusion protein in cynomolgus monkeys (Macaca fascicularis): a single-dose non-GLP (good laboratory practice) study and a repeated-dose GLP study. Gastrointestinal toxicity was closely monitored. In a single-dose study, the safety and tolerability of the recombinant fusion protein were evaluated at doses of 10, 30 and 60 mg / kg compared to vehicle controls, with one male and one female animal in each group. In this single-dose study, no effects on body weight or food qualitative assessments related to the test agent occurred during the entire two-week post-treatment assessment period, and no vomiting or diarrhea was observed. In a repeated-dose GLP study, the safety and tolerability of the recombinant fusion protein was evaluated compared to vehicle controls after continuous administration four times a week at doses of 3, 10 and 30 mg / kg. During the main 28-day study period, three males and three females were included in each group, and after a subsequent 28-day recovery period, two other males and two females in the 30 mg / kg and vehicle control groups were evaluated. No test agent-related effects on food intake were observed in this repeated dose study. Although test agent-related vomiting was observed in this repeated dose study, clinically observed vomiting was only associated with infusion reactions, observed in only one animal (17%) in the 10 mg / kg group and two animals (20%) in the 30 mg / kg group, and was transient. Diarrhea was observed only in the vehicle control group and the 30 mg / kg recombinant fusion protein group, observed in only one (10%) and three (30%) animals, respectively, and was considered a normal phenomenon for this type of procedure and was not related to the recombinant fusion protein. Finally, in this repeated dose study, only at the 10 mg / kg and 30 mg / kg doses, the mean body weight decreased by >10% relative to baseline, and only after the fourth dose of the 10 mg / kg group and the third and fourth doses of the 30 mg / kg group. In summary, except during acute infusion reactions, treatment with the recombinant fusion protein did not result in any clinically significant findings related to food intake, vomiting or diarrhea, and gastrointestinal findings had no effect on the determination of the degree of no adverse events in both studies. These results suggest that the design of recombinant fusion protein alleviates the adverse effects of NRG-1 recombinant protein on the gastrointestinal tract.
[0285] Blood samples (~1 ml) were collected from cynomolgus monkeys at different time points after a single dose of 60 mg / kg of the recombinant fusion protein, and serum was extracted and stored at -80°C until testing. The concentration of the recombinant fusion protein in the serum samples was analyzed by capturing ELISA according to standard procedures. In brief, 96-well plates were coated with recombinant human HER3 protein (R&D System), blocked with BSA and incubated with the test samples. After multiple washes, the plates were incubated with HRP-coupled anti-human IgG Fc antibodies and subsequently detected with TMB substrate. Fig.12The results showed that the pharmacokinetic profile of the recombinant fusion protein was similar to that of IgG antibody. Example 10: Summary of Fc receptor binding kinetic constants
[0286] The binding affinity of recombinant anti-HER3 mAb / NRG-1 fusion protein to Fc receptors was measured using label-free SPR technology. A total of six Fc receptors (each fused to a His tag), including FcγRI (Abcam), FcγRIIa, FcγRIIb, FcγRIIIa (158F), FcγRIIIa (158V) and C1q (Sino Biological) were analyzed for recombinant fusion proteins, recombinant fusion proteins without Fc mutations and anti-HER3 antibodies, respectively. All Fc receptors and test samples were purified by affinity chromatography. All experiments were performed on a Biacore 8K system (GE Healthcare) using HBS-EP+ (10 mM HEPES, 150 mM NaCl, 3 mM EDTA and 0.05% v / v Surfactant P20) as the running buffer. Specifically, the anti-His antibody was coupled in the active and reference flow cells of a CM5 sensor chip by an amine coupling method. Purified His-tagged Fc receptors were captured on the active flow cell of each individual channel via binding to an immobilized anti-His antibody. Capture levels for each Fc receptor were maintained between 80-120 RU. For kinetic analysis, recombinant fusion proteins and all other samples were serially diluted to a total of 6 concentrations ranging from 0.3 nM to 30 nM, and the serial dilutions were injected sequentially through two flow cells of each channel. Multiple analyses were completed in the same run by injecting samples simultaneously on multiple channels.
[0287] The obtained sensor spectra were fitted with a two-state binding model using Biacore 8K evaluation software to extract kinetic constants. The equilibrium dissociation rates (KD) of all analyses are summarized in Table 1 below. The kinetically derived KD values for the binding of the recombinant fusion proteins to FcγRI, FcγRIIa and FcγRIIb were more than 10 times higher than the KD values of the recombinant fusion proteins without Fc mutations and the anti-HER3 antibody, indicating that the affinity is much lower due to specific mutations in the Fc region of the recombinant fusion proteins. For FcγRIIIa (158F) and FcγRIIIa (158V), the Fc mutations resulted in a 2- to 3-fold decrease in the binding affinity of the recombinant fusion proteins, respectively. Binding to C1q was too weak to be detected in all samples.
[0288] To confirm that the recombinant fusion protein has limited Fc effector functions, antibody-dependent cell cytotoxicity (ADCC) was examined using the ADCC Reporter Bioassay from Promega (Madison, WI). This assay uses an engineered Jurkat cell line as effector cells that stably express the FcγRIIIa (V158) receptor and the NFAT response element driving firefly luciferase expression. Rituximab was used as a positive control for this assay and showed strong ADCC activity against CD20-positive Raji cells; while the recombinant fusion protein had no detectable ADCC against HER3-positive target cells (MCF7 or BT474) (data not shown). Table 1: Summary of Fc receptor binding kinetic constants *<LOD - Below the limit of detection (LOD) due to weak binding Example 11: The NRG-1-HER3 recombinant fusion protein shows anti-fibrotic effects in vitro atrial tissue and AF prevention effects in vivo in a mouse model
[0289] Introduction. Atrial fibrillation (AF) is caused by electrical and structural remodeling of the atria, in which inflammation and fibrosis play a role. Current therapies are limited to antiarrhythmic drugs and ablation, but do not address the structural problems. Recent studies have shown that neuregulin-1 (NRG1), a member of the epidermal growth factor family, has anti-fibrotic and anti-inflammatory effects in the myocardium.
[0290] Objective. To test the effects of an exemplary NRG-1 / HER3 antibody fusion protein on atrial fibrosis and AF induction. The NRG-1 / HER3 antibody fusion protein contains an active fragment of NRG-1 and an antagonistic HER3 (ERBB3) antibody, and selectively signals via ERBB4 preferentially over ERBB3.
[0291] Methods. The in vitro fibrosis assay described in Fig.13A was used to induce fibrosis in rat tissue samples in vitro. Atrial samples were collected from male rats (Wistar Han, 10 weeks old), cut into small pieces (1 - 2 mm 2 ) and kept in low serum medium in the presence or absence of the NRG-1 / HER3 fusion protein (5 nM concentration). After 24 - 72 hours, Col1a1 and Col3a1 mRNA were quantified as described in Fig.14A and 14B respectively.
[0292] AF induction was tested in two models. In the first AF model, male mice (C57BL / 6N, 12-15 weeks old) were treated with angiotensin-II (Ang-II, 4 weeks, osmotic minipump, 3000 ng / kg / min) as described in the experimental protocol. Fig.16 In. Fig.18 In the second AF model described in , mice were fed a high-fat diet (HFD, 8 weeks, 60% Kcal fat), which induced severe weight gain (56±3% increase, compared to 23±4% increase on a regular diet), as Fig.19A In both models, AF induction was tested by delivering 5 sessions of programmed electrical stimulation (PES) using an octopole catheter via the jugular vein. Fig.15 AF induction (% of mice induced by ≥3 PES) and duration of PES-induced AF (AF duration) were recorded. Mice were randomized to treatment with vehicle or exemplary NRG-1 / HER3 fusion proteins (2 times / week, 1 mg / kg, IV, n=5-7 / group).
[0293] Results. In cultured atrial samples, the mRNA expression of Col1a1 and Col3a1 gradually increased by 2-3 times over 3 days, as shown in Table 1. Fig.13A and 13B NRG-1 / HER3 fusion protein strongly attenuated this effect by 59±17% (p<0.05). Fig.14A and 14B As shown in . In mice, both Ang-II and HFD significantly increased AF induction and AF duration. In Ang-II mice, NRG-1 / HER3 fusion protein attenuated AF induction (from 57% to 20%), as shown in Fig. 17B As shown in , and AF duration (from 33.3±15.1 to 1.5±1s), as Fig.17A In HFD mice, NRG-1 / HER3 fusion protein significantly attenuated AF induction (from 57% to 0%). Fig. 20B As shown in , and AF duration (from 10.9±3.2s to 0.76±0.5s, p<0.05), as Fig. 20A as shown in .
[0294] Conclusions. These results demonstrate an antifibrotic effect of selective ERBB4 stimulation of atrial tissue with NRG-1 / HER3 fusion protein in vitro and a protective effect against AF in two unrelated mouse models. Example 12: NRG-1 / HER3 antibody fusion protein reduces type I collagen associated with myocardial stiffness
[0295] The Sprague-Dawley rat model of myocardial infarction and systolic heart failure (also known as heart failure with reduced ejection fraction, or HFrEF) employed in Example 7 was used to analyze type I and type III collagen expression. After four weeks of treatment, heart tissue samples were removed, fixed and sectioned as described in Example 7, and stained for type I or type III collagen expression using immunohistochemistry.
[0296] Representative results for type I collagen are shown in Figures 21A to 21F In. Figures 21A to 21F As can be seen in the results, the NRG-1 / HER3 antibody fusion protein administered at 1 mg / kg, 3 mg / kg and 10 mg / kg downregulated the expression of type I collagen by 6.6%, 37.1% and 40.5% respectively compared to the vehicle control. In addition, as shown in Table 2 below, the collagen I / III ratio decreased by 4.7%, 40.8% and 36.6% respectively compared to the vehicle control.
[0297] Table 2. Changes of myocardial collagen △△△p<0.01 indicates statistical significance compared with sham control *p<0.05, **p<0.01 indicate statistical significance compared with vehicle control Example 13: NRG-1 / HER3 antibody fusion protein prevents atrial fibrosis and atrial fibrillation induction in pig DOCA model
[0298] Atrial fibrosis is a substrate for recurrence of atrial fibrillation (AF), and the heavier the fibrosis burden, the worse the treatment resistance and prognosis. The degree of fibrosis predicts prognosis and refractory to therapy. Currently, there is no therapy targeting atrial fibrosis. NRG-1 / HER3 fusion protein is a long-acting neuregulin fusion protein that has been shown to reduce ventricular fibrosis (i.e., has anti-fibrotic properties) in animal models of heart failure via selective stimulation of the ErbB4 receptor. In this example, the ability of NRG-1 / HER3 fusion protein to reduce atrial fibrosis and AF induction in a minipig model of hypertension induced by deoxycorticosterone acetate (DOCA, an aldosterone agonist) was tested.
[0299] Methods: Eighteen Aachener miniature pigs were randomly divided into three groups: control (CTRL), DOCA+vehicle (DOCA+VEH), and DOCA+NRG-1 / HER3 fusion protein. The control group did not receive any therapeutic intervention. Fig. 22To induce hypertension and atrial fibrosis, miniature pigs in the DOCA+VEH and DOCA+NRG-1 / HER3 fusion protein groups were implanted with particles releasing 10 mg / kg DOCA for 60 days. Animals implanted with DOCA were treated weekly with NRG-1 / HER3 fusion protein (0.3 mg / kg; DOCA+NRG-1 / HER3 fusion protein) or its vehicle (DOCA+VEH) starting on the day of implantation (9 doses in total). After 60 days, arterial blood pressure was measured invasively and a decapole catheter was placed in the right atrium. AF induction was tested by performing 50 bursts of rapid pacing and quantified as the percentage of "successful" episodes out of 50 attempts, in which AF could be induced to run for ≥5 seconds after the burst of rapid pacing. Exemplary results of the AF induction test are shown in Fig.23 Middle. Quantification of atrial fibrosis using Masson’s trichrome staining of left atrial specimens isolated after animal euthanasia using ImageJ software.
[0300] Results: The mean arterial pressure in the DOCA+VEH (142±10 mmHg) and DOCA+NRG-1 / HER3 fusion protein (132±15 mmHg) groups was significantly higher than that in the CTRL group (105±8 mmHg, p<0.01), but there was no effect of NRG-1 / HER3 fusion protein ( Fig.24 ).
[0301] like Fig.25 As can be seen in the data, AF induction in the DOCA+VEH group was significantly higher than that in the CTRL group (66 / 250 vs. 9 / 300, p<0.001) and the DOCA+NRG-1 / HER3 fusion protein group (66 / 250 vs. 8 / 300, p<0.001). Similarly, the degree of atrial fibrosis in the DOCA+VEH group was significantly higher compared with CTRL (14.18±1.81 vs. 8.30±2.52, p<0.001) and compared with DOCA+NRG-1 / HER3 fusion protein (14.18±1.81 vs. 10.65±1.59, p=0.0049), as shown in Table 1. Fig.26 Visible in.
[0302] Conclusion: NRG-1 / HER3 fusion protein prevents atrial fibrosis and AF induction in the porcine DOCA model. The effects of NRG-1 / HER3 fusion protein are not related to the effect on blood pressure, but may be related to the reduction of atrial fibrosis.
Claims
1. A method for treating atrial fibrillation and / or cardiac fibrosis in a subject, comprising administering to the subject a recombinant fusion protein comprising a neuregulin-1 (NRG-1) fragment fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb).
2. Use of a recombinant fusion protein comprising a neuregulin-1 (NRG-1) fragment fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb) for use in a method for treating atrial fibrillation and / or cardiac fibrosis in a subject.
3. The use of the recombinant fusion protein according to the method of claim 1 or claim 2, wherein: The cardiac fibrosis includes atrial fibrosis.
4. The method or use of the recombinant fusion protein according to any one of claims 1 to 3, wherein: The NRG-1 fragment comprises the active domain of NRG-1.
5. The method or use of the recombinant fusion protein according to any one of claims 1 to 4, wherein: This NRG-1 fragment contains the ERBB3 / 4 binding domain.
6. The method or use of the recombinant fusion protein according to any one of claims 1 to 5, wherein: The NRG-1 fragment binds to ErbB4 (HER4) and induces signaling therethrough.
7. The method or use of the recombinant fusion protein according to any one of claims 1 to 6, wherein: This mAb inhibits NRG-1 signaling through ErbB3 (HER3).
8. The method or use of the recombinant fusion protein according to any one of claims 1 to 7, wherein: The NRG-1 fragment comprises the NRG-1β2a isoform.
9. The method or use of the recombinant fusion protein according to any one of claims 1 to 8, wherein: The NRG-1 fragment is fused to the C-terminus of the antibody heavy chain via its N-terminal amino acid using a linker.
10. The method of claim 9 or the use of the recombinant fusion protein, wherein: The linker comprises at least one copy of the Gly-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser linker set forth in SEQ ID NO:
5.
11. The method or use of the recombinant fusion protein according to any one of claims 1 to 10, wherein: The C-terminus of the antibody heavy chain comprises the Fc domain of the antibody.
12. The method or use of the recombinant fusion protein according to any one of claims 1 to 11, wherein: This monoclonal antibody is glycosylated.
13. The method or use of the recombinant fusion protein according to any one of claims 1 to 12, wherein: The NRG-1 fragment comprises the amino acid sequence of SEQ ID NO:
4.
14. The method or use of the recombinant fusion protein according to any one of claims 1 to 13, wherein: The mAb comprises the heavy chain amino acid sequence of SEQ ID NO:
2.
15. The method or use of the recombinant fusion protein according to any one of claims 1 to 14, wherein: The mAb comprises the light chain amino acid sequence of SEQ ID NO:
3.
16. The method of claim 15 or the use of the recombinant fusion protein, wherein: The mAb comprises a substitution mutation of at least one of amino acids 234, 239 and 434 of SEQ ID NO:
2.
17. The method of claim 16 or the use of the recombinant fusion protein, wherein: The at least one substitution mutation comprises an L234F mutation, an S239A mutation, an N434A mutation, or a combination thereof.
18. The method or use of the recombinant fusion protein according to any one of claims 1 to 8, wherein: The recombinant fusion protein comprises the amino acid sequences of SEQ ID NO:3 and SEQ ID NO:
14.
19. The method or use of the recombinant fusion protein according to any one of claims 1 to 18, wherein: Relative to the signal induction potential of recombinant NRG-1, the recombinant fusion protein promotes HER2 / 4 signaling over HER2 / 3 signaling.
20. The method or use of a recombinant fusion protein according to any one of claims 1 to 19, wherein: The recombinant fusion protein promotes the proliferation, differentiation and survival of the subject's cardiomyocytes or heart tissue.
21. The method or use of a recombinant fusion protein according to any one of claims 1 to 20, wherein: The recombinant fusion protein attenuates the proliferation of tumor or cancer cells relative to recombinant NRG-1.
22. The method or use of a recombinant fusion protein according to any one of claims 1 to 21, wherein: Administration of the recombinant fusion protein reduces the duration of atrial fibrillation or reduces the frequency of atrial fibrillation.
23. The method or use of a recombinant fusion protein according to any one of claims 1 to 22, wherein: Administration of the recombinant fusion protein reduces signs or symptoms of atrial fibrillation or cardiac fibrosis.
24. The method of claim 23 or the use of a recombinant fusion protein, wherein: Symptoms of atrial fibrillation include irregular heartbeat, palpitations, dizziness, extreme tiredness, shortness of breath, chest pain, or a combination thereof.
25. The method of claim 23 or the use of a recombinant fusion protein, wherein: The signs of cardiac fibrosis include collagen content or deposition, and wherein administration of the recombinant fusion protein reduces collagen content or deposition in cardiac tissue.
26. The method or use of the recombinant fusion protein according to any one of claims 1 to 25, comprising administering to the subject 0.1 mcg / kg to 5 mg / kg of the recombinant fusion protein.
27. A drug kit comprising a therapeutically effective amount of a recombinant fusion protein comprising a neuregulin-1 (NRG-1) fragment fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb) for treating atrial fibrillation and / or cardiac fibrosis in a subject.
